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Abstract
Burkholderia cepacia has become an important cause of lung infections in cystic 
fibrosis sufferers of whom approximately 20 % succumb to severe and often fatal 
necrotizing pneumonia and septicaemia. The factors which cause this are largely 
unknown as are those factors predisposing to epidemic spread. At present, published 
data only confirms that certain strains notably the UK epidemic strain EX 12 can 
spread amongst the CF population.
Another problem facing scientists which also impinges on patients and their carers, is 
the difficulty in isolating B. cepacia in mixed specimens and its subsequent 
identification and differentiation from closely related species which may also colonise 
the CF lung. Identification has recently been compounded by the identification of 
more than one species or genomovar of B. cepacia.
This study compared traditional phenotypic methods of identifying B. cepacia with 
PGR methods and also evaluated direct detection of the organism in sputum by PGR. 
The presence of B. cepacia in the natural environment was determined by culturing 
environmental samples on selective media.
Putative epidemic markers in B. cepacia were detected and this was correlated with 
genomovar group and RAPD fingerprint.
Finally, the distribution of various virulence markers including serum sensitivity and 
presence of EPS were monitored and were also correlated with genomovar group.
The results of this study showed that PGR methods for the identification of B. cepacia 
are more sensitive and specific than traditional methods and allow for its direct 
detection in sputa. Only the UK epidemic strain appears to spread epidemically in the 
UK and this strain is most reliably identified by the presence of the cable pili gene 
{cblA). Serum sensitivity and correlation with strain-type and presence of EPS was 
significant as was the presence of intracellular enzymes and strain or genomovar 
groifp. However the significance of these enzymes in pathogenicity remains uncertain.
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1. Introduction 
1.1. Cystic Fibrosis
1.1.1. The disease
Cystic fibrosis (CF) is the most common inherited disorder affecting 1 in 2000 
Caucasians (Davies 1991). Approximately 4 to 5% of this racial group may be carriers 
of the defective gene but only homozygotes acquire the disease. Relatively few of the 
body’s cells are affected by CF but include the epithelial cells lining the lungs, 
intestine, pancreas and skin (Davies 1991). In normal cells an increase in intracellular 
cAMP allows chloride and water to move firom the cell to the mucosal surface. This 
liquifies the mucous layer covering the epithelium allowing clearance of particles and 
bacteria. In CF cells, chloride and water secretion is reduced and subsequently the 
mucous becomes dehydrated and viscous. The disease itself is characterised by high 
electrolyte concentrations in sweat, male infertility, pancreatic insufficiency leading to 
malabsorption and production of thick sticky mucus in the lungs followed by chronic 
pulmonary infection.
1.1.2. Genetics
In 1989, researchers at the University of Toronto and Michigan located the genetic 
defect that causes CF on chromosome 7 (Davies 1991). The gene spans about 250 kb 
of DNA and is divided into 27 protein coding regions or exons (Knight 1992). In 
epithelial cells this gene codes for a protein known as the Cystic Fibrosis 
Transmembrane Regulator (CFTR). This was believed to function as a channel 
allowing chloride ions to enter and leave cells and which was faulty in CF sufferers
resulting in abnormally salty sweat (Davies 1991; Knight 1992). However, instead of 
an ion channel, the protein more closely resembles a membrane ATP-dependent 
transporter. Removing a segment of DNA from the middle of the gene (R-domain) led 
to an uncontrolled flow of chloride ions across cell membranes suggesting that the R- 
domain codes for a protein that acts as a flap or gate over the pore of the chaimel 
(Davies 1991). It was also discovered that sites on the protein are recognised by 
kinases which add phosphate groups to certain amino acids and it was suggested that 
these negatively-charged groups cause the flap to retract from the cell membrane thus 
leading to the opening of the pore. In CF, the flap appears to block the pore preventing 
transport of chloride ions in the epithelial cells which results in a lack of water 
movement into the airway passages. This in turn leads to the production of 
dehydrated sticky mucus in the lungs which is an ideal breeding ground for bacteria. 
There is, however, more than one genetic defect in the CFTR gene, although most of 
these effect the structure of the CFTR protein. Approximately 85% of CF are caused 
by four mutations; the most common being the AF508 mutation which is characterised 
by deletion of phenylalanine at position 508 in the protein chain (Davies 1991; Knight 
1992). The remaining 15% are caused by rarer mutations (> 800 to date) with some 
being found in only one family. Some mutations result in failure of the CFTR protein 
to be produced. These patients appear to fare better, presumably because there is no 
blocking of the chloride pore. Other patients have normal copies of the CFTR gene 
and so the mutation may be located elsewhere on chromosome 7.
One example where the outward symptoms appear to be directly related to the genetic 
defect is in those CF patients who are homozygous for the AF508 mutation. These 
patients invariably have pancreatic insufficiency (Fiel 1993). The frequency of the
AF508 mutation is significantly lower in the pancreatic sufficient group than the 
pancreatic insufficient group (Santis et al 1990).
The discovery of the CF gene has led to therapeutic trials where the normal CFTR 
gene is introduced into the airways of rats via adenoviruses or liposomes (Davies 
1991). Clinical trials of gene therapy are in progress but so far improvements in 
clinical status have been less dramatic and sustained than expected.
1.1.3. The patients
As recently as 20 years previously, the prognosis for CF patients was poor vdth up to 
10% dying from meconium ileus shortly after birth. Other early problems include 
intestinal blockages due to dehydrated stools and steatorrhoea may also occur. 
However, with improvements in the understanding and treatment of the disease, the 
mean age of survival is now 30 years and beyond and many are able to lead reasonably 
normal lives. Many go on to higher education and careers and partake in most social 
activities. Often CF patients socialise as a group and the CF Trust in the UK and the 
CF Foundation in the US have sponsored summer camps abroad, other social events 
and meetings and conferences for older patients. Interaction between CF patients at 
these events where they can discuss mutual issues and problems is considered to be 
good for their general well being.
The improvements in life expectancy and good health have mainly come about as the 
result of the setting up of specialised CF clinics. These provide advanced medical and 
nursing care, physiotherapy to aid lung clearance and dieticians to advise on the 
necessity of a high energy diet to combat the problems of malabsorption and salt loss. 
Patients are also treated with pancreatic enzymes, anti-inflammatory drugs to prevent 
early lung damage, vitamins and nebulised and intravenous antibiotics. Lung
transplants have also been successfully carried out on patients with end-stage lung 
disease.
However, increased life expectancy has brought about its own problems which mainly 
involve the respiratory system. Severe haemoptysis (bleeding from the lungs) occurs 
rarely in older patients but chronic lung infections due to numerous opportunistic 
bacterial pathogens is common.
1.1.4. Lung infections
Problems of the gastrointestinal tract in CF patients have been adequately managed for 
some years now but lung deterioration due to chronic bacterial infections remains the 
major cause of morbidity and mortality. The lungs of CF patients are normal at birth 
and in theory damage is preventable (Littlewood 1986). Evidence suggests that regular 
culturing of lung secretions and appropriate antibiotic therapy are important in 
minimising early lung damage which in children is usually caused by infections with 
Staphylococcus aureus.
Staphylococcus aureus. The reasons why the CF lung is predisposed to infection with 
S. aureus are not entirely clear. May and Roberts (1969) found that sputum, serum and 
urine from patients with CF support better the growth of S. aureus than specimens 
from controls. They suggested that this may be due to an elevated level of p- 
hydroxyphenylacetic acid which appears to enhance the growth of S. aureus. Schwab 
et al (1993) examined the adherence mechanisms of S. aureus in the CF lung to 
determine whether the airway epithelial cells themselves have specific receptors for S. 
aureus or whether CF isolates of the species have a greater affinity to bind to the 
airways. They found no evidence for the presence of increased or different S. aureus
receptors on CF epithelial cell surfaces but CF isolates did appear to have a greater 
binding affinity for CF airways.
Haemophilus influenzae. This is a significant pathogen in the lungs of children with 
CF and may colonise in place of S. aureus after the latter is eradicated by 
antimicrobial therapy. H. influenzae was more fi-equently isolated fi'om the lower 
respiratory tract of children with CF than those with asthma and a rise in isolation rate 
preceded the development of acute exacerbations (Rayner et al 1990). They also 
showed that treatment was associated with clinical improvement and eradication of 
the organism in most cases.
Pseudomonas aeruginosa. This is the most common coloniser of the lungs of older 
CF children and adults and approximately 80-90% of CF patients develop chronic 
infections (Pier 1998). The main factor thought to be responsible for its persistence is 
a switch to a mucoid phenotype which occurs frequently in the CF lung. This mucoid 
exopolysaccharide (MEP) which is composed of alginate protects the organism fi'om 
host defences. Studies by Santis et al (1990) demonstrated a correlation between the 
CFTR mutation and susceptibility to P. aeruginosa infection in that pancreatic 
sufficient patients were less likely to have chronic sputum colonisation by P. 
aeruginosa than pancreatic insufficient patients. Colonisation was higher amongst 
patients homozygous for the AF508 mutation and who were pancreatic insufficient 
(De Braekeleer et al 1998). Pier (1998) explained this by suggesting that CFTR is a 
specific receptor for P. aeruginosa on epithelial cells which ingest it and then clear it 
fi’om the lungs by shedding. Cells with mutant forms of CFTR such as AF508 have 
difficulty in ingesting the organism resulting in chronic infection. However, this is 
unlikely to be the only reason for P. aeruginosa infection in CF but may help to
explain its persistence in some patients. P. aeruginosa also produces a wide range of 
virulence factors which include a potent cytotoxin, exotoxin A, which inhibits protein 
synthesis, phospholipase C and proteases such as elastase (Wretlind and Pavlovskis 
1981).
Other pathogens Numerous bacterial, viral and fungal pathogens may infect the CF 
lung resulting in varying degrees of morbidity. In some cases bacteria proliferate as 
apparently “harmless” colonisers. Examples include Stenotrophomonas maltophilia 
which occurs occasionally in CF patients especially after courses of broad-spectrum 
antibiotics. Persistent colonisation with this organism may lead to deterioration in 
lung function (Ballestero et al 1995). Pseudomonas species of rRNA group II which 
have recently been transferred to the genus Burkholderia may also be a problem, 
especially B. cepacia which in recent years has emerged as a very important pathogen 
in the CF lung.
1.2. Burkholderia cepacia
1.2.1. History
B. cepacia was first described in the 1940s by Burkholder as a cause of sour rot in 
onions (Burkholder 1950). The rot was found to attack only the outer leaves of the 
bulb resulting in a sour and slippery skin. Microscopical examination of the tissue 
revealed numerous bacteria many of which were harmless saprophytes. The actual 
bacterial pathogen was only present in small numbers amongst the saprophytes and 
was described as a motile non-sporing gram-negative rod. A water-soluble 
yellow/green pigment was produced on nutrient agar distinct from the yellow
fluorescent pigment of P. aeruginosa. However, other characteristics classified it in 
the genus Pseudomonas and he described it as a new species. Pseudomonas cepacia n. 
sp.
1.2.2. Taxonomy
Stanier et al (1966) proposed the name Pseudomonas multivorans for a group of 
aerobic pseudomonads isolated fi'om soil and water which reflected the range of 
organic compounds they used as carbon and energy sources. All the isolates studied 
had multitrichous flagella and accumulated poly->^hydroxybutyrate as a cellular 
reserve material. Most hydrolysed gelatin and produced lecithinase. All produced a 
lipase and could use ammonia and nitrate as nitrogen sources. Pigment production 
was variable and included, yellow, brown, red and purple pigments. Ballard et al 
(1970) examined 18 isolates of P. cepacia fi'om plants and were unable to distinguish 
them phenotypically from P. multivorans isolates described by Stanier et al (1966). 
Two of the P. cepacia isolates were shown by DNA-DNA hybridization, to share a 
level of genetic homology with the type strain of P. multivorans as high as that of 
other isolates of this species. The DNA base composition of some of the P. cepacia 
isolates, also fell in the P. multivorans range of 67-68 G+C moles %. The main 
difference was the ability of P. cepacia to produce onion rot, although some of 
Stanier’s P. multivorans isolates were later shown to have this property. Ballard et al 
(1970) concluded that the two species were synonymous and that the correct 
designation was P. cepacia. Phytopathogenicity was removed as a characteristic of all 
isolates but many of the phenotypic tests described by Stanier for P. multivorans were 
included. He also found that P. cepacia, P. marginata {gladioli) and P. caryophylli 
shared many phenotypic properties and showed DNA-DNA hybridisation homology
with P. pseudomallei and P. mallei. These species subsequently became known as the 
Pseudomallei group.
Jonsson (1970) studied the cultural, biochemical and serological characteristics of 
Pseudomonas isolates described by King as Eugonic Oxidisers Number One (EO-1) 
which were isolated from a variety of clinical sources. On the basis of these findings, 
the name Pseudomonas kingii n. sp. was proposed. Morphological, biochemical and 
carbon utilisation tests carried out by Snell et al (1972) on P. cepacia, P. multivorans, 
P. kingii and EO-1 strains confirmed that P. kingii was a fiirther synonym of P. 
cepacia. Analysis of the fatty acid composition of strains of P. multivorans and P. 
kingii by gas-liquid chromatography irrefutably showed that they were identical 
species (Samuels et al 1973). Similar findings were reported by Sinsabaugh and 
Howard (1975) from a wide range of tests on isolates of P. cepacia, P. multivorans 
and P. kingii.
Palleroni et al (1973) examined rRNA homologies (rRNA-DNA hybridisations) in the 
genus Pseudomonas and proposed five distinct sub-groups. P. cepacia was classified 
in group II along with P. marginata {gladioli), P. caryophylli, P. pickettii, and P. 
solanacearum.
At the meeting of the Judicial Commission of the International Committee of 
Systematic Bacteriology, held in Jerusalem in March 1973, an Ad Hoc committee was 
appointed to review bacterial names (Skerman et al 1980). The intention was to retain 
only names of those taxa which were adequately described and for which a type or 
reference strain was available. P. cepacia lost its validity by exclusion from this 
Approved List of Bacterial Names and hence lost its standing in bacterial 
nomenclature. However, Palleroni and Holmes (1981), revived the name P. cepacia
with a description of the species and its relationship to other species of Pseudomonas 
in rRNA group U. They also designated ATCC 25416 as the type strain.
Yabuuchi et al (1992) proposed that seven species of Pseudomonas rRNA group II 
should be transferred to a new genus, Burkholderia, with B. cepacia as the type 
species. The genus also included B. caryophylli, B. gladioli, B. mallei, B. 
pseudomallei, B. pickettii and B. solanacearum. Two species, B. plantarii and B. 
glumae, were added to the genus on the basis of phenotypic and chemotaxonomic 
characteristics and they were later joined by B. vandii (Urakami et al 1994) and B. 
cocovenenans (Zhao et al 1995), although recently the latter two have been proposed 
as junior synonyms of B. plantarii and B. gladioli respectively (Coenye et al 1999). 
Gillis et al (1995) described nitrogen fixing strains of the same rRNA complex as B. 
cepacia and named them B. vietnamiensis due to their origin from macerates of rice 
cultured in Vietnam. They also demonstrated that B. solanacearum and B. pickettii 
constituted one rRNA branch of Burkholderia whilst the others were segregated into 
another branch which included B. andropogonis comb. nov. Subsequently, the former 
two species were transferred to the genus Ralstonia (Yabuuchi et al 1995). Three 
further pseudomonads (P. glathei, P. pyrrocinia and P. phenazinium) have also been 
proposed for reclassification as Burkholderia (VaiLdammQ et al 1997), (Viallard et al 
1998). B. graminis, B. thailandensis, B. carihensis and B. uboniae have recently been 
proposed as new species (Viallard et al 1998) (Brett et al 1998), (Achouak et al 1999), 
(Yabuuchi et al 2000).
It was becoming increasingly clear to microbiologists that the species B. cepacia was 
not homogeneous but it was the work of Vandamme et al (1997) using a polyphasic 
diagnostic approach that showed that B. cepacia isolates comprised at least five
genomovars. The tests that they carried out included SDS-PAGE of whole cell 
proteins, G+C values, DNA-DNA and DNA-RNA hybridisation experiments, fatty 
acid methyl ester analysis and biochemical tests. Genomovar I was termed B. cepacia 
and included the type strains and plant isolates. Genomovar II was termed B. 
multivorans but genomovars III and IV were not assigned a species name at this time. 
Genomovar V was termed B. vietnamiensis. The reactions of the genomovars in 
biochemical tests are shown in table 1.
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Table 1
Biochemical reactions of the B. cepacia complex and B. gladioli (Vandamme et al
Biochemical reaction 1 n HI IV B.
gladioli
B.
vietnamiensis
Acid production in ASS 
Glucose + +
a
+
b
+
c
+ + +
Adonitol + + + - - + + -
Cellobiose + + + +/- - + +/- +
Dulcitol + + + - - + + +
Fructose + + + - +/- + + +
Inositol + + + +/- - + + +
Lactose + + + + - +/- - +
Maltose + + +- +/- - + - +
Mannitol + + + - - + + +
Raffinose +/- - - - - - +/-
Salicin +/- +/- +/- - - - - -
sorbiol + + + - - + + +
Sucrose +/- - + + - - - +
Xylose + + + +/- - + + +
Acid from
Glucose peptone sugar water +/- + + +/- + +
10% glucose + + + + - + +/- +
10% lactose + + + + - + +/- +
Alkaline reaction in OF - - - - +/- - - -
medium
Casein digestion +/- . +/- +/- +/- +/-
Growth at 42®C - + + +/- + - - -
Growth on cetrimide agar + + + + + + +/- +
Growth on Simmons’ citrate + + + + +/- + + +
Malonate utilisation + +/- +/- +/- +/- + - +
Pigment on tyrosine - - +/- +/- +/- - +/- -
Motility at 37”C +/- + + +/- +/- + - +
Nitrate reduction +/- + - +/- +/- +/- +/- +/-
Oxidative in OF medium + + + + - + +/- +
Urease production +/- + +/- - +\- +/- +/- +
+/- Indicates positive or negative reaction
Subsequently, genomovar IV isolates were designated as B. stabilis due to the highly 
conserved nature of their genomes in contrast to other members of the complex 
(Vandamme et al 2000). More recently, genomovar VI has been described as a 
member of the B. cepacia complex (Coenye et al 2001) and this group can be 
distinguished from the other five genomovars (except for B. multivorans) by 
biochemical tests and SDS-PAGE of whole-cell proteins. The main distinguishing 
features of the genomovars are shown in Table 2.
11
Table 2
Tests which discriminate between members of the cepacia complex
Test Genomovar
I II III IV V VI B. gladioli
Growth at 42®C - + + - - + -
P-Galactosidase activity 
Decarboxylation of:
+ + + + + +
Lysine + V + + + - +
Ornithine 
Oxidation of:
+ + + + - +
Sucrose + - + - + - -
Lactose + + V + + + -
Adonitol + + V + + + -
Maltose + + V + + + -
1.2.3. Habitat
B. cepacia is ubiquitous in the environment and can be isolated from soil, rivers, 
plants and raw milk (Gregory and McNabb 1986). It has the ability to survive in 
nutritionally limited environments and can use a wide range of organic compounds as 
energy sources including penicillin G as a sole carbon source (Beckman and Lessie 
1979). B. cepacia is unusual in that it is both a plant and a human pathogen and it can 
also suppress other plant pathogens. McLoughlin et al (1992) showed that sunflower 
wilt fungus was suppressed in the presence oîB. cepacia leading to increased 
sunflower emergence; although the antimicrobial agents produced by B. cepacia were
12
not the main inhibitors of the fungi. B. cepacia has also been found to reduce 
“damping off’ in plants such as com and pea roots due to the fungus Pythium (Hebbar 
et al 1998), (Parke et al 1991). These and other studies have led to interest in the use 
of B. cepacia as a biopesticide and plant-growth-promoting bacterium. However, this 
is controversial due to the importance of B. cepacia in human disease (Govan and 
Vandamme 1998), (Holmes et al 1998). Butler et al (1995) sampled a large botanical 
complex including a range of soils, aquatic sites and vegetation and did not recover B. 
cepacia as frequently as would be expected except in moist soil or rhizosphere. In the 
home B. cepacia may be found in tap water and on fresh fruit and vegetables but it 
does not heavily contaminate the domestic environment in comparison with other 
Pseudomonas species such as P. aeruginosa, P. putida and P. fluorescens (Mortensen 
et al 1995). In the hospital environment B. cepacia may contaminate stored water, 
distilled water and antiseptic solutions as it can survive for long periods of time in 
nutritionally limited conditions especially if sources of carbon and nitrogen are 
present (Geftic et al 1979). Prolonged survival in antiseptic solutions is believed to be 
due to protection of the organism by cellular and extracellular material forming on 
surfaces (Anderson et al 1991).
1.2.4. Appearance
B. cepacia is a pleomorphic, aerobic gram-negative rod of approximately 0.5 x 2.5 pm 
and motile by means of a tuft of three to eight polar flagella (Gregory and McNabb
1986). It grows on blood agar at 35 to 37 to produce smooth circular non- 
pigmented colonies of approximately 0.5 to 1.0 mm in diameter after 48 h incubation. 
Pigment may be produced on some media such as Pseudomonas P agar. There are two 
main types of pigment which are probably phenazine derivatives. One of these is
13
diffusible and fluorescent whilst the other is a sulphur-yellow diffusible but non- 
fluorescent pigment. More rarely seen are brown, red and purple pigments which are 
usually strain dependent (Gregory and McNabb 1986).
1.2.5. Genetics
B. cepacia possesses an unusually large and complex genome. It contains numerous 
insertion sequences and consists of approximately three large circular replicons 
(Cheng and Lessie 1994). This arrangement probably explains the ability of the 
organism to utilise a wide variety of substrates and to survive in different and often 
unfavourable environments (Holmes et al 1998). It may also account for pathogenic 
versatility and variable antibiotic sensitivity profiles. A comparison of two clinical 
isolates with two agricultural isolates showed that all four clustered within the genus 
Burkholderia but there were differences in the 16S rDNA between the two groups 
(Tabacchioni et al 1995). Indeed a recent study has found that all isolates of B. 
cepacia have between two and four large replicons (>500kbp) but clinical isolates 
were more likely to have three or four replicons than environmental and plant 
pathogenic isolates (Wigley and Burton 2000).
1.2.6. Disease
General infections. B. cepacia rarely causes infections in healthy people and most 
cases occur in patients with an underlying predisposition to infection. Examples 
include osteomyelitis and endocarditis in heroin addicts (Smith et al 1985) (Noriega 
et al 1975) and brain abscess following chronic otitis media treated with contaminated 
ear drops (Hobson et al 1995). It has been reported as a cause of community-acquired 
septicaemia as a secondary consequence of pulmonary infection (Reed 1998) and has
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been linked to primary pneumonia in a previously healthy individual after heavy 
exposure to dust (Dailey and Benner 1968). An outbreak of nosocomial infection due 
to B. cepacia amongst ventilated ITU patients in two US hospitals was attributed to 
contaminated mouthwash (Matrician et al 2000). B. cepacia may be introduced into 
normally sterile sites such as the cerebrospinal fluid to cause meningitis and has been 
implicated in a number of infections including urinary tract infection, endocarditis, 
peritonitis, pneumonia and conjunctivitis. Contaminated disinfectant solutions and 
surgical appliances may be responsible in some cases (Bassett et al 1973), (Berkelman 
et al 1982), (Speller et al 1971), (Hardy et al 1970), (Ederer and Matsen 1972). 
Trench foot. B. cepacia has been shown to colonise the toewebs of troops during 
training in swamp areas (Taplin et al 1971). The swamp waters themselves did not 
yield large numbers of B. cepacia and so it was concluded that damp but otherwise 
intact skin was a suitable site for multiplication of the organism leading to 
hyperkeratotic lesions. This condition also provides evidence for the pathogenic 
potential of environmental isolates.
Chronic granulomatous disease (CGD). This is a hereditrary disease where oxygen- 
dependent killing of microorganisms in neutrophils fails to function due to an absence 
of NADPH oxidase to trap oxygen for the hexose-monophosphate shunt. Oxygen- 
dependent killing of bacteria is brought about by hydrogen peroxide (H2 O2), free 
radicals such as superoxide (O 2) and singlet oxygen (^ 0 2 ). Organisms that produce 
H2 O2 (which is the most important oxygen-derived killing agent in neutrophils), 
contribute to their own death but catalase-producing bacteria such as P. aeruginosa 
and B. cepacia actually break down H2 O2 . P. aeruginosa is not a problem in CGD as 
it is sensitive to oxygen-independent killing mechanisms (Speert et al 1994). B.
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cepacia however, is resistant to nonoxidative bactericidal effects and is an important 
pathogen in CGD patients where it commonly causes pneumonia in previously 
undamaged lungs (O'Neil et al 1986; Speert et al 1994). The infections tend to be 
severe and the slow healing is accompanied by granuloma formation in various 
organs.
Cystic fibrosis. Although not as common as P. aeruginosa, B. cepacia colonisation of 
the CF lung is the cause of extreme concern amongst patients, their carers and 
families. This is because 0-20% of those infected succumb to “cepacia syndrome” 
which is characterised by the onset of a necrotising pneumonia, sometimes with 
septicaemia and often rapidly fatal.
1.3. Burkholderia cepacia in Cystic Fibrosis
1.3.1. General
As well as concern about “cepacia-syndrome”, other anxieties are also raised when 
caring for B. cepacia colonised patients. A major cause of current anxiety is the 
discrimination of B. cepacia-çoûûwQ patients during selection for lung transplants. 
They are believed to be inferior candidates due to persistence of the organism after 
transplant and often have a poor prognosis (Steinbach et al 1994), (Snell et al 1993). 
There is also a social stigma attached to colonised patients who are often segregated in 
hospitals and discouraged from attending summer camps and other events for fear of 
cross-infection. There are many questions and much debate about aspects of B. 
cepacia acquisition and infection in CF sufferers. The most important question is why 
is B. cepacia attracted to the CF lung and what strain factors cause disease? Is only a
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minority of CF strains virulent or does it depend on host factors such as previous 
infections? Also, what is the reservoir of CF infection: do patients acquire the 
organism from the environment and/or other patients and are all strains equally 
transmissible between patients? Some of these problems are discussed in more detail 
in the following sections and although the emphasis is on isolates from CF patients, 
much is also applicable to B. cepacia infection in other diseases.
1.3.2. Isolation
The isolation of B. cepacia from the CF lung and differentiation from organisms such 
as P. aeruginosa, S. aureus, H  influenzae and other gram-negative rods is often 
difficult. To tackle this problem, selective media containing the polymyxin antibiotic, 
colomycin to which the genus is constitutively resistant have been developed and two 
formulations are available commercially: Pseudomonas cepacia (PC) agar (Gilligan et 
al 1985) and Oxidation-fermentation-lactose-polymyxin B (OFPBL) agar (Welch et al
1987). These media suppress the growth of the mixed flora of CF sputum and support 
the growth of B. cepacia better than conventional media. An enrichment broth has 
also been developed which may be more efficient for the isolation of the organism if 
present in small numbers (Cimolai et al 1995). More recently, Henry et al (1997), 
described a medium which was enriched for B. cepacia but more selective against 
other organisms than the media described above. They named this medium B. cepacia 
selective agar (BCSA). Furthermore, the selectivity for B. cepacia was increased by 
the addition of vancomycin.
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1.3.3. Identification
The identification of B. cepacia is also problematic. This is due to the difficulty of 
distinguishing B. cepacia firom other Burkholderia and Pseudomonas species that may 
grow on the selective media. As a general rule, colonies which grow on selective agar 
and prove to be gram-negative rods and producers of oxidase enzyme, oxidise glucose 
and fail to convert arginine can be presumptively classified as B. cepacia subject to 
further test results. However, some strains fi*om CF sputum may be asaccharolytic and 
fail to react in sugar-containing media 
Phenotvpic methods
Probability matrix. Holmes, et al (1986) constructed a computer based probability 
matrix for the identification of Gram-negative non-fermentative bacteria. This gives 
the probability of a particular species to produce a positive or negative result in a 
number of tests. Although some strains of B. cepacia were atypical and difficult to 
identify, the identification rate achieved for the species by this approach was 91.5%. 
The biochemical tests used to differentiate B. cepacia fi-om other species are listed in 
Table 3.
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Table 3
Biochemical reactions used in the identification of B, cepacia
Reaction
Acid production in ammonium salt sugars
Reaction in oxidation/fermentation medium
Casein digestion
Growth on cetrimide agar
Growth on Simmon’s citrate
Nitrate reduction
Urease production
Oxidase production
Commercial kits. A number of kits including Rapid NF Plus and API RAPID NFT 
kits are available for the identification of gram-negative rods. These have the 
advantage over conventional tests in that they are more rapid but have the drawback of 
misidentifying other closely related species (Kiska et al 1996). More recently. Shelly 
et al (2000) found that more than 10% of isolates identified as B. cepacia by referring 
laboratories proved to be other gram-negative species which may colonise the CF lung 
especially B. gladioli. However, conventional tests are not without their problems and 
if the reactions are weak or the incubation times are shortened, false-negative or 
positive results may occur which may lead to misidentification of isolates (Burdge et 
al 1995).
Genomovars. As described earlier, B. cepacia and closely related species have been 
classified into genomovars on the basis of the test reactions (section 1.2.2.)
19
(Vandamme et al 1997). Many of the biochemical tests used to define genomovars are 
also used to identify B. cepacia (Holmes et al 1986). This method of grouping also 
enables identification of the closely related species B. gladioli and B. vietnamiensis 
which may be misidentified as B. cepacia and also allows classification of 
asaccharolytic variants of B. cepacia. These isolates are more likely to be mistaken for 
alkaline-producing gram-negative rods because of their weak alkaline or negative 
reaction in Hugh and Leifson’s 0/F glucose medium. These variants are now 
classified as B. cepacia genomovar III biovar c.
Genotvpic methods
A problem with biochemical tests, apart fi*om rapid identification kits, is the need for 
specific reagents and the time taken to obtain a result may be impracticable for many 
diagnostic bacteriology laboratories. Also, despite the extended range of phenotypic 
identification tests, some B. cepacia isolates remain difficult to identify 
unequivocally. Indeed, some isolates of the strain of B. cepacia prevalent in outbreaks 
among CF patients in Scotland and the north of England, has been reported to have 
phenotypic features indicative of both B. cepacia and B. gladioli (Simpson et al
1994). This has led to research into alternative methods of identification. O'Callaghan 
et al (1994) developed a polymerase chain reaction (PCR) and DNA hybridisation 
assay based on 16S rRNA sequences for the identification of B. cepacia and B. 
cepacia specific 16S rRNA sequences were also exploited by Campbell et al (1995). 
Tyler et al (1995) opted for 23 S rRNA sequences to generate oligonucleotide primers 
for amplification of a region specific for B. cepacia and utilized sequences from the 
internal transcribed spacer (ITS) region of 16S-23S rRNA for the identification of B. 
gladioli. More recently, a number of studies have focused on PCR methods for the
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identification of the individual genomovars of the B. cepacia complex (Bauemfeind et 
al 1999), (LiPuma et al 1999), (Vandamme et al 2000), (Whitby et al 2000), 
(Mahenthiralingam et al 2000).
1.3.4. Epidemiology
The demonstration of transmissible strains of B. cepacia amongst CF patients has 
caused much anxiety during recent years due to their association with morbidity and 
mortality. Contact with other patients is good for their general well-being and 
draconian segregation policies introduced both in the hospital and socially has caused 
both emotional and administrative problems not to mention possible legal challenges 
of these policies.
Environmental transmission
Many patients harbour sporadic strains which may suggest that their isolates are 
acquired from environmental sources (Steinbach 1994). However, B. cepacia is 
apparently infrequent in the home and on food (Mortensen et al 1995) and the 
suggestion that it is ubiquitous in the natural environment has been questioned by 
Butler et al (1995). Furthermore, environmental and clinical isolates often show 
differences in their DNA profile and pathogenic activity for plant tissue (Butler et al
1995), (Bevivino et al 1994).
Hospital transmission
The survival of B. cepacia in antiseptic solutions has afready been mentioned 
(Anderson, et al 1991), (Geftic et al 1979). This suggests that the hospital 
environment could be a major source of B. cepacia for CF and other susceptible 
patients. Colonisation and even outbreaks have been attributed to contaminated 
antiseptic solutions and equipment including nebulisers and spirometry mouthpieces
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used by CF patients (Gravel-Tropper et al 1996), (Reboli et al 1996), (Hutchinson et 
al 1996), (Govan et al 1993). Nosocomial acquisition of R  cepacia was shown to be 
related to humidifier and nebuliser treatment but not to antibiotic usage or room 
sharing and socialising with other patients and B. cepacia failed to be recovered in air 
samples after coughing, or on the hands of patients, nurses and physiotherapists 
(Burdge et al 1993). Doring et al (1997), found that B. cepacia was less ubiquitous in 
the hospital environment than P. aeruginosa as it was isolated only once from a sink 
drain in a CF ward. Furthermore, it was never isolated from patients or staff but they 
were able to demonstrate that both B. cepacia and P. aeruginosa embedded in sputum 
survived sufficiently well to be transmissible by hand shaking for up to three hours. B. 
cepacia can also persist in CF patients who have received lung transplants. Steinbach, 
et al (1994) found that CF patients at a transplant centre all had unique strains of B. 
cepacia. They also showed that disseminated infection following lung transplantation 
was due to the same strain as that isolated preoperatively.
Patient to patient transmission
There is evidence to suggest that some strains of B. cepacia are directly transmissible 
between CF patients and a number of studies have shown that segregation of patients 
as out- and in-patients in hospital reduces the rate of acquisition of the organism and 
its spread (Paul et al 1998), (Muhdi et al 1996), (Thomassen et al 1986). Cross 
infection has also been documented as a result of social contact and this raised the 
issue as to whether attempts should be made also to segregate patients outside of 
hospital (LiPuma et al 1990), (Govan et al 1993), (Smith et al 1993), (Smyth et al
1993).
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Govan et al (1993) described an epidemic strain that spread between clinics in 
Edinburgh and Manchester. This strain had been imported from North America to the 
UK as a result of CF patients staying at a summer camp in Canada. This is now the 
predominant strain in the UK CF population and was named ET12 by Johnson et al 
(1994). Some isolates give characteristic dry sticky colonies on agar and produce a 
melanin-like brown pigment. Some isolates are highly resistant to most antibiotics and 
may also possess characteristics of both B. cepacia and B. gladioli (Simpson et al
1994). The UK epidemic strain has since been classified in B. cepacia genomovar III 
(Vandamme et al 1997).
Tvping of B. cepacia
A  number of phenotypic and genotypic typing systems have been employed to 
determine the relatedness of B. cepacia isolates for epidemiological studies (Rabkin et 
al 1989), (Ouchi et al 1995).
Biotyping. B. cepacia is fairly uniform in its biochemical characteristics but some 
test properties are sufficiently variable to be used as biotype markers. Identifying 
common strains of B. cepacia involved in outbreaks by biochemical tests has had 
variable degrees of success but biotyping is neither as sensitive nor specific as 
genotypic methods (Rabkin et al 1989), (Ouchi et al 1995). Strains indistinguishable 
by genotyping may exhibit marked phenotypic variability and be classified as different 
biotypes.
Antimicrobial susceptibility. B. cepacia is intrinsically resistant to a number of 
antimicrobial agents and thus the relatedness of isolates cannot be accurately 
determined by antimicrobial susceptibility. This is due to variabilty in susceptibility
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amongst isolates of the same genotype and the instability of susceptibilities of 
individual colonies within an isolate (Rabkin et al 1989), (Pitt et al 1996). 
Bacteriocin typing. Bacteriocins are proteinaceous substances which are active 
against strains of the same or closely related species. They are non-replicative but 
many Pseudomonas bacteria have phage tail type bacteriocin structures. Isolates may 
be typed by the spectrum of production and/or sensitivity to bacteriocins. Both these 
features have been found to be stable and reproducible in B. cepacia and the method 
has been reported to give good discrimination (Govan and Harris 1985).
Serotyping. B. cepacia can be distinguished by somatic antigen and flagellar antigen 
serotypes. The somatic or 0-antigens are lipopolysachharide (LPS) in nature and at 
least two schemes have been described (Heidt et al 1983), (Nakamura et al 1986). 
Further classification of strains is afforded by flagellar H-antigens which may be 
detected by immobilisation of cells with specific antibodies. Serotyping is a very 
useful method for epidemiological studies but discrimination is inadequate for strain 
identification due to the limited number of serotypes.
Ribotyping. This method detects variation in rDNA gene loci. The rRNA operon in 
bacteria is highly conserved and is a good indicator of phylogenetic relationships 
between species. Providing there are sufficient copies of the operon and an 
appropriate restriction endonuclease is used, ribotyping can also distinguish between 
strain populations. B. cepacia chromosomal DNA is digested with the restriction 
endonuclease EcoBl and the resultant fi*agments are separated on an agarose gel 
before transferring to nitrocellulose and hybridising with E.coli rRNA. Isolates within 
a ribotype may differ fi*om each other by three or fewer bands whereas those within 
the same subribotype have identical banding patterns or differ from each other by
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single bands. Rabkin et al (1989) found this method to be sensitive and specific for B. 
cepacia. Ribotyping has also been exploited by LiPuma et al (1988) who 
demonstrated B. cepacia isolates of the same ribotype within CF centres and Pitt et al 
(1996) identified more than 50 ribotype patterns in UK CF isolates and found the 
epidemic strain (ribotype 1) in 10 different CF centres.
PCR Ribotyping. Traditional ribotyping is time consuming and technically 
demanding. PCR ribotyping on the other hand is more rapid and simpler to perform. 
This technique detects length polymorphisms in the intergenic spacer region between 
16S and 23 S rRNA genes using primers complementary to highly conserved 
sequences. This method has been shown to give identical patterns for B. cepacia 
strains involved in patient-to-patient transmission but also distinguishes unrelated 
strains (Kostman et al 1992), (Ryley et al 1995).
Randomly Amplified Polymorphic DNA (RAPD). This PCR-based DNA 
fingerprinting method is best suited for a large throughput of isolates. As with PCR 
ribotyping, it detects length polymorphisms but differs in that it employs random 
primers. Mahenthiralingam et al (1996) evaluated a number of primers and selected 
one for RAPD fingerprinting of a collection of isolates of B. cepacia from CF and 
non-CF patients and the environment. They found the method to be reproducible and 
discriminatory and more sensitive than PCR ribotyping. It was more comparable with 
ribotyping and pulsed-field gel electrophoresis (PFGE) and gave similar strain 
groupings. The major problem with RAPD is that the results vary firom laboratory to 
laboratory making inter-laboratory comparisons difficult.
Multilocus Enzyme Electrophoresis (MLEE). This technique separates isolates on 
the basis of differences in enzyme electrophoretic mobilities and is a good indicator of
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population structure and phylogenetic relationships. Johnson et al (1994) was able to 
differentiate isolates of B. cepacia according to origin by MLEE and found that 
environmental, CF and other nosocomial isolates clustered in separate groups. Isolates 
from an individual CF centre often had the same MLEE profile but were sometimes of 
different libotypes. This work ascribed individual strains to clonal complexes and 
notably classified the UK epidemic strain in clone ET 12.
Pulsed-Field Gel Electrophoresis (PFGE). This is probably the most discriminatory 
DNA typing method for a wide range of bacteria and offers restriction enzyme 
analysis of the entire genome. Rare cutting restriction endonucleases are employed to 
produce fragments of >50 kb. To achieve separation of such large DNA fragments, the 
electric field is alternated in two directions in a pulsed current with smaller and larger 
fragments being separated by shorter and longer pulse times respectively. Some 
investigations have employed both ribotyping and PFGE for B. cepacia outbreaks, 
with ribotyping forming the primary division and the PFGE pattern discriminating 
further between strains where possible (Steinbach et al 1994), (Ouchi et al 1995), (Pitt 
et al 1996).
Epidemic markers
In recent years a number of studies have described the presence of epidemic markers 
associated with strains of B. cepacia linked to outbreaks in the CF population. These 
markers do not necessarily have an obvious role in transmissibility but their presence 
may confirm the identification of an epidemic strain.
Cable pill. Sajjan et al (1995) described giant fibres known as cable pili which were 
present on isolates of B. cepacia from a Toronto CF centre. These pili are believed to 
mediate adherence to CF respiratory mucins and this enhances colonisation of lungs
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by B. cepacia. A 22-kDa adhesin is located along the length of the fibre as well as at 
the appendage in order to maximise adhesion. The pilus is encoded by the 
chromosomally located cblA gene which can be detected by PCR. Sun et al (1995) 
characterised the genetic relatedness of isolates expressing cable pili fi-om the 
outbreaks in Toronto and showed by PFGE and ribotyping that they were all grouped 
in the same lineage. Interestingly, isolates fi-om the Edinburgh CF centre which were 
epidemic in the UK were also grouped in this lineage.
Insertion sequence hybrid. Tyler et al (1996) identified a hybrid of two insertion 
sequences \S402 and IS7556 which was exclusive to epidemic strains from Canada 
and the UK. Its role in transmission of strains however, is unknown.
Burkholderia cepacia epidemic strain marker. Mahenthiralingam et al (1996) using 
RAPD typing with a 10-base primer (P272), identified a conserved 1.4 kb open 
reading frame (ORF) in the DNA fingerprint of seven epidemic B. cepacia strains 
including one positive for chlA. This sequence was absent in isolates fi-om sporadic 
infection. The ORF showed homology with a family of negative transcriptional 
regulators and was termed B. cepacia epidemic strain marker (BCESM) 
(Mahenthiralingam et al 1997). As with the insertion sequence hybrid, BCESM has no 
known role in transmission.
1.3.5. Virulence
B. cepacia is rarely pathogenic in healthy subjects and a suitable animal model has 
not been identified. However in CF patients clinical outcome varies fi-om 
symptomless pulmonary carriage to severe necrotising pneumonia and septicaemia. 
Little is known about the factors which determine outcomes and B. cepacia does not 
appear to produce cytotoxic enzymes equivalent to exotoxin A and exoenzyme S as in
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p. aeruginosa (McKevitt and Woods 1984). Indeed, host factors probably dictate 
whether the organism will simply colonise the lung or progress to extensive 
pulmonary damage and systemic spread. Nevertheless, a number of virulence factors 
both structural and chemical have been attributed to B. cepacia.
Adherence
The ability of a pathogen to adhere to host mucosal or cell surfaces is often the first 
step in the infection process (Nelson et al 1994). B. cepacia from CF patients binds 
equally efficiently to both CF respiratoiy mucin and non-CF intestinal mucin (Sajjan 
et al 1992). The receptors are thought to be carbohydrates present on all normal 
mucins but the quantity produced in CF airways and its accessibility to inhaled 
organisms may increase the susceptibility of the lung to colonisation There is also 
some evidence that isolates which bind to mucin are associated with a poorer 
prognosis in the patients from which they were isolated. The adhesins present on B. 
cepacia which determine this binding may be expressed as polar or peritrichous 
fimbriae. Kuehn et al (1992) identified al 6 kDa protein, which was believed to be a 
fimbrial subunit of B. cepacia, that showed homology with P. aeruginosa PAK 
fimbriae. These fimbriated B. cepacia cells showed a much higher level of adherence 
than non-fimbriated cells. Sajjan and Forstner (1992) however, isolated a 22 kDa 
protein from mucin-binding B. cepacia which was distinguishable from pilin proteins 
of Escherichia coli (typel pilus) and P. aeruginosa (PAK and PAOl) fimbriae. As 
stated earlier, strains with the 22 kDa protein pilus (cable pili) have increased 
adherence and a greater propensity for epidemic spread (Sajjan et al 1995), (Sun et al
1995). More recently it has been shown that only cable-piliated isolates bound 
preferentially to CF airway tissue compared with non-CF tissue (Sajjan et al 2000).
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The receptor involved was identified as a 55 kDa protein known as cytokeratin 13 
which is synthesised in response to epithelial tissue injury and so is normally present 
inthe CF lung.
Invasion
Pathogens which can invade host cells have an advantage over extracellular 
organisms that are exposed to immunological defences and antibiotics. B. cepacia has 
been shown to invade epithelial cells in the lung by parasite-mediated endocytosis and 
to replicate intracellularly (Bums et al 1996). It may also transcytose the epithelium 
causing systemic spread which would explain its potential to cause septicaemia. 
Indeed, patient isolates appear to exhibit a higher capacity to invade and establish a 
greater number of organisms per epithelial cell than environmental strains (Bums et al 
1992) (Tipper e ra /1998).
Semm resistance
It is clearly in the interests of a potential pathogen to be able to protect itself from host 
defence mechanisms. One way in which this may be achieved is by synthesis of an 
outer cell layer of capsule or slime. This has already been referred to in relation to P. 
aeruginosa and its production of an alginate capsule in the CF lung. Some strains of 
B. cepacia do produce a capsule but it is chemically distinct from alginate. An outer 
membrane structure which serves as a defence mechanism in gram-negative bacteria 
is the long oligosaccharide side (0-side) chain of LPS which in some species may 
consist of up to 40 repeated units of 3-4 sugar residues. This stmcture sterically 
hinders complement molecules fi-om reaching the cell surface to form membrane 
attack complexes in complement-mediated lysis. However, some bacterial species lose 
their 0-side chains during the infective process as is the case with many isolates of P.
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aeruginosa from the CF lung. These are referred to as ‘rough’ phenotypes and are 
more susceptible to complement-mediated serum killing than ‘smooth’ phenotypes 
with complete 0-side chains. It is unclear whether other gram-negative species 
colonising the CF lung undergo phenotypic changes from smooth to rough LPS. 
Certainly B. cepacia has not been shown to do this and many CF isolates exhibit 
rough LPS phenotypes (Butler, unpublished). The serum resistance of isolates of B. 
cepacia from CF does not correlate strictly with smooth and rough LPS phenotypes 
and other factors presumably play a role in the susceptibility of a strain to serum 
killing (Butler et al 1994).
Toxins and enzvmes
Adherence to tissues, invasion into cells and evasion of host defences assist a 
colonising pathogen to survive although some damage to host tissues may occur as a 
result of an exaggerated inflammatory reaction to the bacteria as occurs with P. 
aeruginosa in the CF lung. However, toxins and/or hydrolytic enzymes have a direct 
pathological effect on host cells and may therefore play an important role in the 
pathogenesis of the organism.
Lipases. Phospholipids are important components of eukaryotic cell membranes, 
acting as support structures for membrane proteins and protecting the cell from the 
external environment. Membrane phospholipids consist of a water soluble head of 
phosphatidylcholine (lecithin) or phosphoiylinositol linked to a hydrocarbon chain 
(Titball, 1998). As a consequence, a number of bacterial species produce 
phospholipase enzymes which target specific regions of the phosopholipid. These 
enzymes may be grouped according to the site of cleavage into phospholipases C, D,
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Al, and Ai with phospholipase C (a lecithinase) being the best characterised to date. 
Lysis of eiythrocytes by phospholipase C has been demonstrated in vitro. Both P. 
aeruginosa and B. cepacia have a haemolytic and a non-haemolytic phospholipase C 
and recently the non-haemolytic phospholipase C of B. cepacia was isolated and 
characterised (Weingart and Hooke 1999). In the lung, lecithinase appears to degrade 
phosphatidylcholine leading to tissue colonisation (Shortridge et al 1992). Lonon et al 
(1988) were unable to detect phospholipase C activity in culture supemates of 10 
clinical isolates of B. cepacia. They did, however, record lipase activity on 
polyoxyethylene sorbitans (Tweens). These included Tween 20,40, 60 and 80 which 
are esters of lauric, palmitic, stearic and oleic acids respectively. The role of these 
lipases in pathogenicity is uncertain and may be linked to nutrition. Purified lipase 
from B. cepacia when injected intravenously into mice produced no detrimental 
effects (Lonon et al 1988). Gessner and Mortensen (1990) examined lipase production 
in CF isolates and control strains and found that most hydrolysed Tween 80 and 
produced lecithinase activity on solid egg yolk medium. Similar findings were earlier 
described by McKevitt and Woods (1984).
Proteases. The proteases of pathogenic microorganisms are widely held to be 
responsible for aiding the spread of the pathogens through destruction of tissues. 
Gessner and Mortensen (1990), found that most CF and non-CF isolates of B. cepacia 
were proteolytic on various protein substrates, although activity on any substrate was 
not universal. None of the isolates produced collagenase or elastase. However, an 
extracellular proteinase from culture supernatants of B. cepacia was purified by 
McKevitt et al (1989) who found that it was antigenically similar to the elastase 
produced by P. aeruginosa.
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Haemolysin. The ability to lyse erythrocytes may be important in the pathogenicity of 
a number of bacterial species. Mention has already been made of the haemolytic 
activity of phospholipase C of P. aeruginosa and B. cepacia. Nakazawa et al (1987) 
screened isolates of B. cepacia for extracellular products and found that although 70% 
produced protease, lipase and lecithinase, only 4% were haemolytic . The latter 
isolates also produced the other three enzymes. Characterisation of the haemolysin 
from one isolate showed that it was most active on human eiythrocyes but also lysed 
horse, sheep, chicken and rabbit erythrocytes. Similar results were reported by 
Gessner and Mortensen (1990).
Endotoxin. Endotoxins in contrast to exotoxins are heat-stable polysaccharides which 
are bound to cells and released on cell growth and lysis. In gram-negative bacteria, 
endotoxins are LPS molecules consisting of lipid A, core oligosaccharide and O- 
oligosaccharide side-chains. The toxicity of LPS is due entirely to lipid A and 
therefore rough mutants despite their susceptibility to serum killing, are nonetheless as 
potentially toxic as their smooth counterparts. Endotoxin activates the pathways of 
inflammation, blood-clotting, fibrinolysis and complement via the alternative 
pathway. It is taken up by phagocytes such as neutrophils and Kupffer cells which 
release their lysosomes and endogenous pyrogens outside of the cell. Endogenous 
pyrogens are responsible for fever while lysosomes stimulate vasoactive mediators of 
inflammation. Zughaier et al (1999) compared LPS from B. cepacia, P. aeruginosa 
and S. maltophilia in stimulating human monocytes to release TNF-a and found that 
LPS from B. cepacia had CD 14 dependent TNF-a inducing activity considerably 
greater than the LPS from the other two pathogens. This may explain why acute lung 
inflammation is more often experienced in B. cepacia-co\omsQ& CF patients. They
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also found that LPS from B. cepacia stimulated monocytes to over-produce 
superoxide anion which is important in the respiratory burst. The respiratory burst 
could however be inhibited by the melanin-like pigment produced by some strains and 
which can be detected on tyrosine agar (Zughaier et al 1999).
Other enzymes. Many other enzymes are produced by B. cepacia but their role in 
pathogenicity is unknown. Examples include catalase and oxidase, nitrate reductase 
and urease. Some are probably not involved in the disease process but are necessary 
for nutrition. Indeed, the UK epidemic strain often exhibits variants which are 
asaccharolytic, non-proteolytic, non-haemolytic and non-lipolytic but are equally 
associated with transmission and a fatal outcome (Wilsher et al 1997), (Clode et al 
1999). Nevertheless, Gessner and Mortensen (1990) noted differences between CF 
and non-CF isolates of B. cepacia for some enzymes such as catalase, urease and 
nitrate reductase.
Siderophores
To overcome the problem of iron limitation during host colonisation, microorganisms 
have evolved ways of sequestering iron in a utilisable form. One way is to produce 
high-affinity iron-binding compounds known as siderophores {iron bearers) which 
chelate ferric iron from the host in a form that can be assimilated. Iron starvation leads 
to the synthesis of siderophores which are veiy efficient at scavenging iron when it is 
in short supply. This is followed by the induction of specific transport systems for 
ferricsiderophore reception or binding and internalisation (Briat, 1992). There are 
three classes of siderophores; hydroxamates, catechols and miscellaneous unclassified 
compounds.
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Sokol (1986) screened B. cepacia isolates from CF patients for the production of the 
siderophore pyochelin which is produced by all clinical isolates of P. aeruginosa. 
Approximately half of them produced it and most of these were from patients with 
severe infections. Of the pyochelin-negative isolates, just over a half were isolated 
from patients with mild infections. They also showed that pyochelin-negative isolates 
took up externally supplied pyochelin which increased the dissemination of the 
isolates in a rat lung model and raised the question of whether synergy occurred 
between pyochelin-negative B. cepacia and P. aeruginosa in the CF lung (Sokol and 
Woods 1988), (Sokol, 1986). Around about the same time, another siderophore 
produced by B. cepacia was discovered in iron-deficient growth conditions (Meyer et 
al 1989). This was named cepabactin and may also be produced by other non- 
fluorescent pseudomonads. Subsequently, Sokol et al (1992) isolated a novel 
siderophore in ethyl acetate extracts of culture supernatants of B. cepacia which had 
neither the characteristics of hydroxamates nor catechols and so was placed in the 
miscellaneous class. They named the siderophore azurechelin due to its blue 
fluorescence under UV light. In a medium containing transferrin, azurechelin was able 
to compete with the transferrin for iron and promote the growth of two siderophore- 
negative B. cepacia isolates. It was further demonstrated using radiolabelled iron, that 
azurechelin can only remove iron from transferrin at acid pH such as at sites of 
inflammation. Azurechelin was later identified by Visca et al (1993) as salicylic acid 
by thin layer chromatography. Stephan et al (1993) described novel linear 
hydroxamate/hydroxycarboxylate siderophores in B. cepacia known as omibactins. 
These were designated omibactin -C4, -C6 and -C8 and all possessed the same 
peptide sequence but had slight differences in the acyl residues bound to ornithine at
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position one. Omibactins are the first peptide siderophores isolated from non- 
fluorescent pseudomonads (Stephan et al 1993). Subsequently, Meyer et al (1995) 
showed that omibactin-mediated iron uptake was independent of acyl chain length and 
was a common iron transport system in Burkholderia species but not in other 
Pseudomonas species. More recently, production of the four siderophores pyochelin, 
cepabactin, azurechelin and omibactins by CF B. cepacia isolates has been correlated 
with RAPD type; omibactins being the most common (Darling et al 1998).
Antibiotic resistance
B. cepacia is intrinsically resistant to most antibiotics due to a highly impermeable 
and selective outer membrane. It is resistant to yRlactam antibiotics and can even 
utilise penicillin G as a carbon source. It is also constitutively resistant to 
aminoglycosides and other agents commonly used in the treatment of gram-negative 
infections such as polymyxin B. Susceptibility to carbapenems is variable (Lu et al 
1997). Another problem is the difficulty in estimating the level of antibiotic that will 
be attained in bronchial secretions (Pitt et al 1996). Desai et al (1998) showed that 
resistance of B. cepacia to antibiotics such as ceftazidime and ciprofloxacin increased 
just before the cells entered the stationary phase of growth. They also showed that 
biofilm or biomass grown B. cepacia (as may occur in the CF lung), are less 
susceptible to antibiotics than planktonic cells. The susceptibility to an antibiotic may 
also decrease during therapy and this is shown by the appearance of different 
antimicrobial sensitivity pattems in isolates of the same strain from the same patient 
(Pitt et al 1996). However, some success in treatment of CF B. cepacia infections has 
been demonstrated. The carbapenem meropenem, has been shown to be effective 
against many multiresistant B. cepacia isolates (Ciofti et al 1996). Synergistic effects
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can be demonstrated using antibiotics such as ceftazidime with amikacin or 
ciprofloxacin (Lu et al 1997) and some non-antimicrobial agents e.g. chlorpromazine 
and prochlorperazine may enhance the action of antibiotics such as gentamicin and 
ceftazidime against the species (Rajyaguru and Muszynski 1998).
1.4. Aim of study
The first part of this study will concentrate on comparing traditional phenotypic 
methods of identifying B. cepacia with present day genotypic methods. Acid 
production in ammonium salt sugars, plate enzyme assays, rapid ID kits and PCR for 
target genes within the 16S and 23 S rRNA operon of B. cepacia, will all be evaluated 
for specificity and sensitivity. Furthermore, the efficiency of PCR assays in detecting 
B. cepacia in primary sputum specimens will be assessed and compared with 
conventional culture methods on selective and non-selective media.
The presence of B. cepacia in the natural environment will be determined by culturing 
environmental samples on selective media and confirming the identity of any isolates 
by the above methods.
The distribution of putative epidemic markers in B. cepacia isolates and their 
correlation with genomovar group (determined by the above plate and tube assays) 
and RAPD fingerprint will be investigated.
Finally, the distribution of various virulence factors in B. cepacia will be monitored. 
These will include LPS constitution and serum resistance, and production of various 
enzymes specifically protease, lipase, lecithinase, gelatinase, haemolysin and onion- 
macerating enzymes. The presence or absence of these will also be correlated with 
genomovar group.
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2. Methods
2.1. Bacterial isolates
The type strains of B. cepacia, B. gladioli and P. aeruginosa were obtained from the 
National Collection of Type Cultures (NCTC) and the American Type Culture 
Collection (ATCC). Other Burkholderia and Ralstonia species were provided by the 
LMG Culture Collection, Belgium and the National Collection of Plant Pathogenic 
Bacteria (NCPPB) UK. Isolates of other gram-negative species were selected from 
collections kept in the Laboratory of Hospital Infection (LHI). Clinical isolates of R 
cepacia from CF patients included those sent to LHI for identification or typing. Some 
isolates from the ribotyping study of Pitt et al (1996) were also included. 
Environmental isolates of R  cepacia and some representatives of the UK epidemic 
strain including CF 5610 from the index case, were provided by Prof JRW Govan, 
University of Edinburgh Medical School, Scotland. An isolate of Clostridium 
perfringens was provided by Dr. Moira Brett of The Food Safety Microbiology 
Laboratory (FSML) at CPHL.
2.2. Sputum samples
Sputirai samples from R cepacia- positive CF patients were kindly provided by the 
Royal Brompton Hospital, Sydney Street, London, UK.
2.3. Identification
2.3.1. Biochemical identification and enzyme production
All media were prepared in the Media Department at CPHL except where stated. 
Isolates were tested in the API 20NE gallery (Biomerieux, Basingstoke, UK) and
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examined for gram-stain reaction, motility, production of catalase, oxidase, nitrate 
reductase and growth on MacConkey agar, B. cepacia selective media (Mast, Bootle, 
UK), cetrimide and poly-hydroxybutyrate agars.
Overnight cultures of B. cepacia on nutrient agar (NA) 30 were suspended in 
sterile distilled water to give a light suspension of 0.5 McFarland equivalents and 20 
pi drops were spotted onto substrate plates or agar slopes in tubes. These were 
incubated at 30 and the results (as determined by the changes described below) 
were read after 5 days. API 20NE strips were inoculated as per manufacturer’s 
instructions and read after incubation at 30 for 48 h.
Casein agar plates were prepared at a concentration of 2.5% skim milk (w/v). A 
positive reaction was indicated by a zone of clearing in the opaque medium around the 
bacterial growth.
Tyrosine plates were prepared at a concentration of 0.5% (w/v). Tyrosine hydrolysis 
was indicated by clearing in the agar around the colonies. Some B. cepacia isolates 
also produced a brown melanin-like pigment on this medium which was recorded. 
Gelatin plates were prepared at a concentration of 0.4% (w/v). Gelatin hydrolysis was 
detected by clearing around the growth after flooding the agar surface with 30%
trichloracetic acid. _________
Egg yolk emulsion plates were prepared at a concentration of 10% (v/v). Lecithinase 
production was indicated by a zone of turbidity developing in the medium around and 
under the bacterial growth.
Tween 20 and 80 were added to molten nutrient agar at a concentration of 1% (v/v). 
Lipase production was indicated by a precipitate around the bacterial colonies.
Blood plates were prepared in LHI as described in section 2.7.2.
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Enzyme production detected on the above media contributed to identifying and 
genomovar grouping B. cepacia and for a comparison with the production of 
extracellular virulence factors in section 3.5.1.
Ammonium salt sugars were prepared as agar slopes with the appropriate 
carbohydrate added at a concentration of 1% (v/v). A positive reaction due to acid 
production was indicated by a colour change from green to yellow.
Hugh and Leifson’s agar media in tubes were prepared with glucose at a 
concentration of 1% (v/v). Isolates of B. cepacia were inoculated by stabbing to the 
bottom of the tube using a thin loop. Typical, oxidative B. cepacia turn the upper part 
of the medium yellow, while assacharolytic variants form a blue colour.
2.3.2. PCR identification
Primer sets
Oligonucleotide primer pairs for the amplification of specific regions of B. cepacia 
16S and 23 S rRNA and the internal transcribed spacer ITS region of B. gladioli, were 
synthesised by Cruachem Ltd, Glasgow, UK. The sequences are shown in Table 4.
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Table 4
Primer sets used for confirmation of B. cepacia and B. gladioli
Primer Ref Sequence Target Amplicon 
size (bp)
Reference
PI PC480
PC1250
5 ’GGTACCGGAAGAATAAGC3 ’ 
5 ’CTGTTCCGACCATTGTAT3 ’
16SrRNA 
B. cepacia
770 O’Callaghan 
et al (1994)
P2 PCI
PC2
5’GCTGC GGATG CGTGC TTTGC 3’ 
5’GCCTT CTCCA ATGCA GCGAC 3’
23S rRNA 
B. cepacia
323 Tyler et 
a /(1995)
P3 PSRl
PSLl
5’ TTTCG AGCAC TCCCG CCTCT GAG 3’ 
5’AACTA GTTGT TGGGG ATTCA TTTC 
3’
16S rRNA 
B. cepacia
209 Campbell et 
a /(1995)
P4 PGl
PG2
5’ TTCAA TGACA AACGT TCGGG 3’ 
5’ GCTTT CGCTT GACAG GCC 3’
ITS rRNA 
B. gladioli
274 Tyler et 
a / (1995)
DNA extraction
Crude bacterial DNA was prepared by emulsifying five colonies of 48 h growth from 
NA in 100 pi of sterile tissue culture water (Sigma, Dorset, UK). Cell walls were 
disrupted in a Dri-block (Techne, UK) at 100 ®C for 5 min., vortexed and centrifuged 
(lEC Micromax) at 13,000 g  for 5 min. For the PCR, 3 pi of the supernatant was 
added to 12 pi of water; a water blank (15 pi) was also included.
PCR
PCR reagents were added to the samples prepared above to give a final volume of 
25 pi. The cocktail included 100 pmol of each of a primer pair, 50 pmol of MgCl2 ,
2.5 pmol of each of the deoxynucleotide triphosphates, 1.25 U of Taq DNA 
Polymerase and 2.5 pi of lOx PCR buffer (Life Technologies, Paisley, UK). For a 
multiplex PCR, each extra primer added replaced 1 pi of the water.
Amplification was carried out in a Thermal cycler (Techne) for 25 cycles. DNA was 
denatured at 96 ®C for 5 min for 1 cycle, and at 96 ®C for 15 s for cycles 2 to 25. The 
optimum armealing conditions were determined between temperatures of 58 ^C and
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63 °C for 30 s and primer extension was at 72 for 90 s. An additional primer 
extension was carried out at 70 for 5 min.
Detection of products
A 1.5% (w/v) Nusieve agarose gel (Flowgen, Sittingboume, UK) was prepared in 
60 ml of 0.5% 10 X TBE buffer (Life Technologies). The PCR products were 
separated at 100 V for 1.5 h and molecular weights were determined by comparison 
with a 123 bp ladder (Life Technologies) and the positive control NCTC 10661.
2.4. Detection of B. cepacia in sputum
2.4.1. Sputum preparation
Sputum was treated according to the method of Ochert et al (1994). Sputum samples 
were treated with 2% N-acetyl-L-cysteine (w/v) (BDH, Poole, UK) in N-acetyl-L- 
cysteine buffer (Woodhams and Mead 1965) in a ratio of 1:1.and incubated at room 
temperature until the viscosity was reduced. The samples were then inoculated onto B. 
cepacia selective media and NA and incubated at 30 ®C. Each sample was centrifuged 
at 13000 g  for 20 min in a microfuge and the deposit resuspended in cold phosphate 
buffered saline (PBS). This was repeated twice and the deposit resuspended in five 
times its volume of sterile tissue culture water. After mixing thoroughly, an equal 
volume of 25% chelex (Bio-Rad Laboratories Ltd, UK) (w/v) in sterile tissue culture 
water was added. This was vortexed for 10 s and incubated in a 56 ®C waterbath for 
30 min, vortexed again and heated in a 95 ®C waterbath for 8 min. Finally, the sample 
was cooled on ice, vortexed and centrifuged at 13000 g for 10 min.
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2.4.2. Detection of B. cepacia
For PCR detection of B. cepacia in sputum, 3 pi of the supernatant was added to 12 pi 
of sterile tissue culture water with a water blank of similar volume. The procedures 
were then followed as in section 2.3.2.
2.5. isolation of B. cepacia from naturai environments
2.5.1. Sampling
Two environmental complexes were chosen. One was the botanical gardens at Kew, 
and the other was a reservoir in North London. Various sites in these two locations 
were sampled. Sterile swabs were used to collect samples and these were immediately 
placed into 10 ml aliquots of Malka minimal broth (Appendix 1) supplemented with 
300 U of colistin per ml.
2.5.2. Isolation and identification
The Malka broths were incubated for 5 days at 30 and a loopful plated onto B. 
cepacia selective media. The plates were incubated for two days at 30 ®C. Any 
colonies growing on the selective medium were tested for oxidase production and for 
oxidation in 0/F medium. Any isolates which were positive for one or both tests were 
confirmed as B. cepacia by PCR as in section 2.3.2.
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2.6. Epidemicity factors
2.6.1. PCR for the detection of epidemic markers
Control isolates
Representative isolates from outbreaks in the UK, ineluding the UK epidemic strain, 
were selected. NCTC 10661 was included as a negative control as were the B. gladioli 
strains ATCC 25417 and NCTC 12378.
Primers
Oligonucleotide primer pairs (Cruachem Ltd) for the detection of the genes encoding 
cable pili, the insertion sequence hybrid and the B. cepacia epidemic strain marker are 
shown in Table 5.
Table 5
Primer sets for the detection of epidemic markers in B. cepacia
Ref Sequence Target Amplicon
(bp)
Reference
CBLl
CBL2
5’ CCAAAGGACTAACCCA 3’ 
5’ ACGCGATGTCCATCACA 3’
CblA 664 Sajjan et 
6f/(1995)
IS402A
IS1356B
5’CAACCGAGACTGAGGAGATG 3’ 
5’ TCCGGCGACACCTCGATGCC 3’
IS hybrid 592 Tyler et al 
(1996)
BCESMl
BCESM2
5’ CCACGGACGTGACTAACA 3’ 
5’ CGTCCATCCGAACACGAT 3’
Epidemic
marker
1.400 Mahenthir- 
alingham et
a / (1996)
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PCR
DNA extraction, PCR reagents and detection of PCR products were as described in 
preceding sections.
2.6.2. Random Amplified Polymorphic DNA typing
Preparation of DNA
Bacterial DNA for RAPD typing was prepared by the guanidium thioeyanate-EDTA- 
sarkosyl (GES) extraction method of Pitcher et al (1989). DNA was diluted 1 in 100 
in distilled water and quantified in a Ultrospec III Spectrophotometer (Pharmacia) 
using the formula below.
Absorbancc2 6o x 5.0 = pg/pl DNA
Samples were diluted to give DNA concentrations of 50 ng in 15 pi of sterile tissue 
culture water for use in the PCR.
RAPD PCR
The sequence of the RAPD primer P272 was 5’ AGCGGGCCAA 3’ 
(Mahenthiralingam et al 1997). PCR was carried out in a 25 pi volume. This 
contained 25 pmol of primer 272, 50 pmol ofMgCli,
2.5 pmol of each of the deoxynucleotide triphosphates, 1.25 U of Taq DNA 
Polymerase and 2.5 ul of 10 x PCR buffer (Life Technologies). Amplification was 
carried out in a TouchDown Thermal cycler (Techne) for 45 cycles. DNA was 
denatured at 95 ^C for 5 min for 1 cycle, and 95 ^C for 1 min, 36 ^C for 5 min, and 72 
®C for 2 min for cycles 2 to 45. PCR products were detected as in preceding sections.
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2.7. Putative virulence factors of B. cepacia
2.7.1. Extracellular virulence factors
Lecithinase production in broth culture
Broth cultures of B. cepacia and Clostridium perfringens were grown in tryptone soy 
broth (TSB) and peptone water broth (PWB) at 30 for 48 h and Robertson’s 
cooked meat (RCM) broth at 37 for 48 h respectively. The bacteria were deposited 
by centrifugation and doubling dilutions of 0.5 ml of the supernatant were prepared in 
0.05 M Hepes buffer (Sigma). Egg yolk substrate was prepared by adding egg yolk 
emulsion (Oxoid) to 0.05 M Hepes buffer in a ratio of 1:5. This was clarified with 
20% NaCl (w/v) (Sigma) and filtered through a 0.45 pm membrane filter (Sartorius) 
under vacuum; 0.5 ml of substrate was added to each dilution of supernatant and 
incubated at 37 for 2 h. Lecithinase production was evident by the appearance of 
turbidity in the clarified egg yolk. The highest dilution of supernatant showing 
turbidity was taken as the titre of lecithinase activity.
Phospholinase C production
This was based on a modification of the method of Berka et al (1981) where 
phospholipase C hydrolyses y?-nitrophenylphosphorylcholine (NPPC) with the 
production of the yellow chromogen p-nitrophenol. Agar grown isolates of B. cepacia 
were incubated for 48 h at 30 in TSB. The tubes were vortexed briefly (Vibro 
Gene, Stuart Scientific, UK) and the absorbances of 1 ml samples read at 540 nm in a 
Pharmacia LKB Ultrospec III spectrophotometer. The cells were deposited by 
centrifiigation and 100 pi of supernatant was added to 900 pi of NPPC reagent
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(Sigma) and incubated at 37 for 1 h. The absorbance at 405 nm was recorded and 
phospholipase C activity was calculated as follows.
Phospholipase C = Absorbance at 405 nm 4- Absorbance at 540 nm 
Protease production in broth culture
Protease production was measured by a modification of the method of Kreger and 
Gray (1978).
Preparation of standard curve
Trypsin (Sigma) concentrations of 5,10,15,20 and 25 pg/ml were prepared in 
duplicate in 0.5 ml aliquots of protease assay buffer (0.2 M Tris (hydroxymethyl) 
aminomethane). To each of these was added 0.5 ml of 5 mg/ml azocasein suspension 
(Sigma). After incubation at 37 for 45 min, the enzyme action was stopped by the 
addition of 3.0 ml of cold 5% (w/v) trichloroacetic acid (TCA). Undigested azocasein 
was removed by centrifugation at 3000 g for 10 min and 2 ml of the supernatant was 
neutralised with an equal volume of 0.5 M NaOH and the absorbancy read at 420 nm. 
A standard curve was plotted as trypsin concentration against increasing absorbancy 
due to release of azo dye from the casein.
Protease production assav
B. cepacia were grown for 48 h at 30 and 37 in TSB and PWB. The cells were 
deposited by centrifugation at 3000 g  for 20 min and 0.5 ml of the supernatant was 
mixed with 0.5 ml of azocasein (5 mg/ml). The same procedure as above was
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followed and the absorbance at 420 nm was used to estimate the concentration of 
protease in the supernatant.
2.7.2. Haemolytic activity and serum sensitivity
Haemolvsin production
Plate assay. Isolates were tested for their ability to lyse red blood cells from a variety 
of species. Venous blood samples were obtained from sheep, horse, rabbit, fowl and 
human blood group “O”. Two ml volumes in 10 mm diameter tubes, were centrifiiged 
at 3000 g  for 20 min and the packed cell volume was estimated against volumes of 
water. The remainder of the blood was centrifiiged as above and the cell deposit was 
washed thrice in phosphate buffered saline (PBS). Packed cells were added to 
peptone water agar at 56 to a concentration of 5% (v/v) except for the horse red 
cells which were used at 7% (v/v). 10 ml volumes of this agar were dispensed into 9 
cm petri dishes and set plates were dried for 15 min at 37 °C. Plates were inoculated 
with a suspension of bacteria at a concentration of 0.5 McFarland units in sterile 
distilled water and incubated in a moist atmosphere in a plastic box at 30 and 
examined daily for 5 days for zones of haemolysis.
Broth culture. Red blood cells were prepared as above and resuspended to a 
concentration of 1%. Isolates were grown for 48 h at 30 and 37 in TSB as a rich 
growth medium and PWB as a poor growth medium. The broth cultures were 
centrifuged at 3000 g  for 20 min and doubling dilutions of the supernatants were made 
in PBS. 50 pi aliquots of these dilutions were mixed with an equal volume of 1% red 
cell suspension in a microtitre plate. A control well of PBS and red cells served as a 
negative control and distilled water and red cells as a positive control. Two sets of 
microtitre plates were prepared and incubated at 37 and 4 for 2 h and examined
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for haemolysis in comparison with controls. The titre was taken as the highest dilution 
giving haemolysis equivalent to the positive control.
Serum sensitivity
Blood samples were collected from three healthy volunteers. The red cells were 
centrifuged (Denley BS 400) at 3000 g for 20 min and the serum pooled, aliquotted, 
stored at -20 and used within a month.
Isolates of B. cepacia were grown on NA plates for 48 h at 30 and 2-5 colonies 
were inoculated into TSB and incubated at 30 for a further 48 h. The broth culture 
was diluted 1 in 10 (10 pi and 90 pi) with Hank’s buffered salt solution (HBSS) (Life 
Technologies). This was further diluted in logarithmic steps to give 10' ,^ 10' ,^ 10"^ ,
10'  ^and 10'  ^dilutions and 20 pi of each were spotted onto NA plates.
50 pi of each dilution was mixed with 50 pi of pooled normal human serum (NHS) in 
the wells of a microtitre plate. Control wells of 50 pi of culture dilution and 50 pi of 
HBSS were also prepared. The wells were sealed with a plastic cover and the plate 
was shaken briefly on an IKA Schuttler MTS 4 and incubated at 37 ®C. After 3 h,
20 pi samples from each well were spotted onto NA plates and the microtitre plate 
reincubated. This was repeated after 6 h and the plate discarded. All NA plates were 
incubated at 30 for 48 h and the growth was recorded as confluent (CL), semi- 
confluent (SCL), ++, + or +/-. Where there were less than 10 colonies, these were 
counted.
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Preparation of LPS extracts
A modification of the method of Hitchcock and Brown (1983) was used to prepare 
LPS extracts. Isolates of B. cepacia were grown in 3 ml of TSB and incubated at 30 
for 48 h. The cells were deposited by centrifugation (MSB Coolspin 2) at 3000 g 
for 15 min. The supernatant was discarded and the cells were resuspended in 100 pi of 
2 X sample buffer by vortexing. (Appendix 2). The suspension was boiled in a water 
bath for 10 min and 100 pi of distilled water was added to each tube and the entire 
contents transferred to a 1.5 ml eppendorf tube containing 40 pi of (0.25% w/v) 
protease K (Sigma) stock solution (Appendix 2) and incubated in a waterbath at 60 
for 2 h. The extracts were then stored at -20 ^C.
Blocking of serum killing bv incubation with LPS extracts
Serum samples (fi*om serum sensitive isolates) and broth cultures were prepared as
above. The broth cultures were diluted to 10'  ^and 50 pi of this dilution was mixed
with 50 pi of NHS in microtitre plate wells and control wells of broth culture and
HBSS were also prepared. A further 50 pi of NHS was mixed with an equal volume
of LPS extract and incubated at 37 ^C. The order and contents of the wells were as
follows.
A
B
C
D
HBSS + broth culture 
NHS + broth culture 
NHS + LPS extract 
HBSS + NHS
E HBSS + LPS extract
After incubation at 37 for 3 h, 20 pi samples from rows A and B were spotted onto 
NA and incubated at 30 for 48 h. 50 pi of a 10'  ^dilution of the isolate under test
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was added to rows C, D and E and re-incubated for a further 3 h. After incubation, 
wells C to E were spotted onto NA and incubated at 30 for 48 h.
SDS-PAGE of LPS extracts
SDS-PAGE was carried out according to Laemmli’s method (1970). Two mini-gels 
(Appendix 3) were prepared in side-arm flasks. The resolving gel was prepared first 
and degassed for 15 min. The gel plates were cleaned and assembled with a gasket 
between them as a sealant and Temed (Sigma) was added with gentle mixing. The 
solution was pipetted into the gel mould to a level 1 cm below the comb edge and 
covered with water to exclude air. The stacking gel was prepared similarly and 
pipetted into the gel mould after the resolving gel had set and the water had been 
removed. The comb was immediately put in place taking care to exclude air bubbles.
The gel was left to set at room temperature for 1 h, the comb and sealant was removed 
and the gel was placed in an electrophoresis tank (Bio-Rad) containing the reservoir 
buffer. Care was taken to remove bubbles trapped under the gel. Proteinase K treated 
LPS extracts stored at -20 were defrosted and samples were loaded into the wells
with a Hamilton syringe (Sigma) using a range of volumes to determine the optimum 
amount of LPS. The gels were run at 50 mA (109 V) for approximately 2 h.
Detection of bands
After electrophoresis, the gels were placed in a fixing solution (Appendix 3) with 
0.7% periodic acid and shaken at room temperature for 5 min. They were rinsed twice 
with distilled water followed by washing 6 times in distilled water with 5 min shaking 
between each wash. The silver stain (Appendix 3) was prepared by adding ammonium
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hydroxide to sodium hydroxide and then gradually adding silver nitrate solution with 
gentle mixing followed by the water. After the final wash, the gel was placed in the 
stain and shaken gently for 10 min. The gels were rinsed twice with distilled water and 
washed 6 times as above and the developing solution (Appendix 3) was added. The 
gels were gently shaken until bands appeared when the developing solution was 
replaced with distilled water. The gels were rinsed thoroughly before photographing.
2.7.3. Onion maceration assay
Representatives of clinical and environmental isolates of B. cepacia were compared 
for their ability to digest onion tissue (Wigley and Burton 1999). Large onions were 
cut horizontally into slices of approximately 5 mm in thickness and placed into 9 cm 
plastic petri dishes. Nicks of approximately 2 mm in depth were made in the inner 
region with a sterile scalpel blade and 100 pi of 48 h TSB cultures of B. cepacia were 
applied. Controls of P. aeruginosa and sterile saline were also included. The tests 
were incubated in a sealed plastic container with moistened tissue paper at 30 ^C for 
48 h and onion slices were examined for colour and texture changes compared with 
the saline control. The surface of the onion was also swabbed and inoculated onto 
selective medium to determine the survival of the isolate.
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3. Results 
3.1. Identification of Burkholderia cepacia
3.1.1. Biochemical identification of B. cepacia and enzyme production
All isolates were confirmed as B. cepacia by their reactions in API 20NE, gram-stain, 
production of catalase and oxidase and growth on B. cepacia selective medium, 
cetrimide and polyhydroxybutyrate agars, acid production in ammonium salt sugars, 
growth at 42^C the Hugh and Leifson’s O/F test, hydrolysis of casein, tyrosine, 
gelatin, tween 20 and 80 and egg yolk agar substrate. The results for the reference 
strains and the percentage positives for 122 CF and three environmental isolates are 
shown in Table 6 and illustrated in Figures 1 to 4.
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Figure 1 Casein medium showing strong, 
medium, weak and no proteolysis.
Figure 2 Tyrosine medium showing 
lysis by 3 of 4 isolates and production 
of a melanin-type pigment by one 
isolate.
Figure 3 Tween 80 medium showing strong 
hydrolysis in three isolates and weak 
hydrolysis in one isolate.
Figure 4 Lecithin medium showing strong 
production of phospholipase in 3 isolates and 
weak production in one isolate.
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3.1.2. PCR Identification
The primer pair Pc 480 and Pc 1250 was found to be sensitive for the detection of B. 
cepacia over a range of annealing temperatures but also produced bands with B. 
gladioli and Achromobacter species. This was not affected by raising the annealing 
temperature and at temperatures above 60 ^C, the clarity of all bands was reduced.
This primer pair was therefore considered to be unsuitable for further evaluation.
The reactions of Burkholderia, Ralstonia and P. aeruginosa strains with the three sets 
of primers are shown in Table 7 and illustrated in Figure 5 as a multiplex PCR.
Table 7
Reactions of reference strains of Burkholderia and Ralstonia with primer sets
Species Strain no. P2 P3 P4
B. cepacia NCTC 10661 + + -
B. cepacia NCTC 10744 + + -
B. cepacia ATCC 29424 + + -
B. cepacia ATCC 25608 + + -
B. cepacia ATCC 27515 + + -
B. cepacia ATCC 17460 + + -
B. cepacia ATCC 25610 + + -
B. cepacia ATCC 17765 + + -
B. gladioli NCTC 12378 - - +
B. gladioli ATCC 25417 - - +
B. gladioli ATCC 10247 - - -
B. gladioli ATCC 10248 - - +
B. glumae LMG 1277_ - + . - ..
R. plantarii LMG 10908 - - -
B. vietnamiensis LMG 6998 + - -
B. vandii LMG 16020 + + -
R. solanacearum LMG 2295 + - -
B. andropogonis LMG 2126 - - -
B. caryophylli LMG 2155 - + -
B. cocovenenans LMG 11626 + - +
R pickettii NCTC 11149 - - -
Ps .aeruginosa NCTC 10332 - - -
P2:23S rRNA for B. cepacia 
P3:16S rRNA for B. cepacia 
P4: ITS for B. gladioli
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Figure 5 Multiplex PCR with three primers (see Table 7) and reference strains o i Burkholderia 
spp and other species. Lane 1: B. cepacia NCTC 10661; lane 2: B.cepacia NCTC 10774; lane 3:
B. cepacia ATCC 25417; lane 4: B. gladioli NCTC 12378; lane 5: B. gladioli ATCC 10248; lane 6: 
B. gladioli ATCC 25417; lane 7: R. pickettii NCTC 11149; lane 8: B. cocovenenans LMG 11626; 
lane 9: R, solanacearum LMG 2295; lane 10: B. caryophylli LMG 2155; lane 11: B. vandii LMG 
16020; lane 12: B. glumae LMG 1277; lane 13: B. vietnamiensis LMG 6998; lane 14: B. plantarii 
LMG 10908; lane 15: B. andropogonis LMG 2126; lane 16: Ps aeruginosa NCTC 10332; lane 17: 
Ps aeruginosa NCTC 10662; lane 18: A. baumannii; lane 19: S. maltophilia; lane 20: water blank; 
lane 21:123 bp size markers.
The optimal annealing temperature for each of the primers was 63 and all B. 
cepacia reference strains produced amplicons with both sets of homologous primers 
but not with the B. gladioli primers and vice versa. However, one reference strain of 
B. gladioli failed to react with primer P4. Four other Burkholderia spp. and the R. 
solanacearum VQÎQVQncQ strain were positive in the PCR with either primer P2 or P3 
but only B. vandii reacted with both primers. B. andropogonis, R. plantarii and R. 
pickettii were negative with each of the three primer sets.
Over 18 months, 177 isolates were submitted for species confirmation by clinical 
diagnostic laboratories as presumed B. cepacia from CF patients and most isolates 
grew on the selective medium. Table 8 summarises the results of the PCR with the 
three primer pairs.
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Table 8
Reactions of presumptively identified cepacia* with primer sets
Biochemical Identification Number P2 P3 P4 No reaction
Typical B. cepacia 78 75 75 3 0
Asaccharolytic B. cepacia 15 15 15 0 0
“R cepacia** 5 0 0 0 5
B. gladioli 11 10 10 0 1
P. aeruginosa 28 0 0 0 28
Other glucose nonfermenters 24 0 0 0 24
Glucose fermenters 3 0 0 0 3
Not identified 13 0 0 0 13
Total 177 100 100 3 74
100 isolates reacted with primers P2 and P3. Of these, 75 were typical of B. cepacia in 
biochemical tests, 15 were asaccharolytic and 10 gave biochemical reactions most 
consistent with an identification of B. gladioli. None of the latter isolates formed 
products with primer P4. However, P4 reacted with three biochemically typical B. 
cepacia isolates. Five clinical isolates which were negative in the PCR, grew on the 
selective medium and were classified by colonial morphology, pigment and other 
phenotypic tests as closest to B. cepacia ’ although the API 20NE classified them as 
‘doubtfiil profile’ for the species. The 24 other glucose non-fermenters included 
alkaline forming pseudomonads and S. maltophilia; 28 strains proved to be P. 
aeruginosa and three others fermented glucose. None of these reacted in the PCR. Ten
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environmental isolates of B. cepacia from the Edinburgh Botanical Garden were 
confirmed by PCR as was the UK epidemic strain.
3.2. Detection of B. cepacia In sputum
The results of PCR detection of B. cepacia in sputum and the correlation with 
isolation of the organism, are shown in Table 9. Figure 6 illustrates the PCR products 
after gel electrophoresis.
Table 9
Detection of B, cepacia in sputum and its isolation and identification
Growth from No. sputa PCR No. PCR No. isolates biochemically
sputa on positive with positive isolates identified
medium primers with primers
No. PC NA P2 P3 P2 P3 B. cepacia Others Others
sputa on PC onNA
35 16 29 20 32 15 15 15 1 11
Figure 6 PCR on CF sputum isolates using B. cepacia specific 
16S and 23S rRNA primers. Lane 1:123 bp ladder; lanes 2 to 
10: sputum samples from presumptive B. cepacia positive CF 
patients; lane 11: jB. cepacia NCTC 10661; lane 12 B. gladioli 
NCTC 12378; lane 13 water blank.
1 2 3 4  5 6  7 8 9 10 1112
13
The 16S rRNA primer pair P3 generally gave stronger reactions than the 23 S rRNA 
primer pair P2 which in some cases failed to produce a band. This is also illustrated in 
Figure 6. Thirty two out of the 35 sputum samples were positive with the 16S rRNA 
primer pair. Of the three negative samples, one failed to yield bacterial growth on 
either medium, the second grew gram-negative rods on NA and PC agar which were
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identified by API 20NE as Bordetella bronchiseptica and the third grew P. aeruginosa 
onNA.
B. cepacia could not be isolated from 16 PCR-positive sputa. This may have been due 
to the organism being non-viable or that the cell numbers were too low to be 
detectable by culture. However, B. cepacia was cultured from the 16 remaining 
sputum samples on NA and PC agar. Other organisms especially staphylococci were 
also grown from some of the sputum samples.
3.3. Isolation of B. cepacia from natural environments
Tables 10 and 11 show the results of growth following enrichment on PC agar from 
samples taken from two environmental sites.
Table 10
Isolation of organisms from botanical garden
Area Growth on 
PC agar
H&L Oxidase
Temperate soil .
Temperate soil + Alkaline +
Humid soil + Alkaline +
Tropical orchids -
Tropical moss -
Temperate orchids -
Temperate moss -
Soil in moist tropics -
Soil in moist tropics + Alkaline +
Pond in moist tropics + Alkaline +
Soil in dry tropics -
Soil in dry tropics -
Soil in dry tropics + Alkaline +
Soil in wet tropics -
Pond in wet tropics + No reaction -
Camiverous plants -
Humidfier spray in wet tropics -
Soil in wet tropics -
Tropical ferns -
Soil in temperate zone + No reaction -
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Table 11
Isolation of organisms from reservoir
Area Growth on H&L Oxidase
________________ PC_agar_________________
Soft mud
Water next to boating club 
Sediment from above 
Water under bridge 
Sediment from above 
Tree bark scrapings 
Playing field soil 
Water next to playing field 
Sediment from above 
Water next to jetty 
Sediment from above
No B. cepacia was isolated from either environmental complex. The alkaline 
producers from the botanical garden were probably Alcaligenes species.
3.4. PCR for the detection of epidemic markers and RAPD typing
Control isolates
Results of the reactions of the control isolates with the primers for the detection of 
epidemic markers and their correlation with RAPD profile, are shown in Table 12 and 
illustrated in Figure 7.   —
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Table 12
Comparison of RAPD profiles of B, cepacia and related species and their 
reactions with 3 primers for the detection of epidemic markers
PCR reactions
Strain number RAPD CblA IS Hybrid BCESM
*CF 5610 Epidemic + + +
01394 Nonepidemic - - +
ID 1091 ^ Epidemic + + +
ID 1092^ Epidemic + + +
ID 1118 Nonepidemic - - +
ID 5318 Epidemic + + +
ID 5566 Epidemic + + +
ID 1120 Nonepidemic - - +
ID 1100 Epidemic + + +
ID 5314 Nonepidemic - - -
CF 1382 Epidemic + , + +
ID 5306 Epidemic + + +
ID 1122 Nonepidemic - - +
ID 5308 Epidemic + + +
ID 5309 Epidemic + + +
NCTC 10661" Nonepidemic - - -
ATCC 25417" Nonepidemic - - -
NCTC 12378" Nonepidemic - - -
* Control UK B. epidemic strain
" = Asaccharolytic strains 
*= B. cepacia 
B. gladioli
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R /\P D  P 2 7 2
CZb>ly^
IS hybrid
BCES/vt
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
Figure 7 CF isolates of B.cepacia showing RAPD fingerprinting and corresponding PCR 
detection of the cblA gene and IS hybrid and BCESM genes. Arrows indicate isolates giving 
RAPD profiles indistinguishable from the UK epidemic strain. Lane 19 is a waterblank
The optimum annealing temperature for primer pair CBLI and CBL2 was 58 and 
for primer pairs IS402A and IS1356B and BCESMl and BCESM2 it was 63 ®C. The 
UK epidemic strain from the index case CF 5610 and all the isolates which were 
indistinguishable from this strain, were positive for all three epidemic markers but 
NCTC 10661 and the two B. gladioli reference strains were negative for all three. The 
other isolates from outbreaks in the UK were negati\^ for and the IS hybrid but 
all except for one were positive for BCESM.
The results of RAPD fingerprinting and presence of epidemic markers for 116 CF 
isolates are shown in Table 13.
62
Table 13 Numbers of epidemic and non-epidemic isolates of R. cepacia and 
presence of epidemic markers
Isolates RAPD CBLA present IS hybrid present BCESM present
UK epidemic 39 39 37 39
Non-epidemic 77* 0 0 11
* Includes four small clusters of cross-infection involving two to three patients.
The results in Table 13 show that one third of the 116 isolates are the UK epidemic
strain and of the epidemic markers, only cblA was exclusively present in all the
epidemic isolates.
3.5. Putative virulence factors of B. cepacia
3.5.1. Extracellular virulence factors
The results of enzyme production in plate assays in section 3.1.1, show that CF 
isolates of B. cepacia varied in their ability to produce proteolytic and phospholytic 
enzymes. However, a positive reaction in a plate assay does not necessarily mean that 
the isolate produces the enzyme extracellulary. To test whether B. cepacia from CF 
patients produced lecithinase, phospholipase C and proteolytic activity in broth 
culture, representative isolates were selected for testing including those giving strong, 
weak and no reaction in the corresponding plate assay.
Lecithinase production
Table 14 shows the results of lecithinase activity in doubling dilutions of six isolates 
of B. cepacia grown in TSB and PWB and a C. perfringens control grown in RCM.
Table 14
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Lecithinase production by B. cepacia in broth culture
Dilutions
Isolate Plate
assay
Broth Neat 10' 10^  10" 10'' 10" Titre of
lecithinase
activity
1 TSB
2 - TSB
3 + TSB
4 ++ TSB
5 + TSB
6 + TSB ++ 4- -f 4-/- 10"
1 PWB
2 - PWB
3 + PWB
4 ++ PWB
5 + PWB -
6 + PWB + - - - - 1
C.
perfringens
++ RCM 44- 4 - 4 - 4 - 4- +!- 10^
Only one B. cepacia isolate gave a turbid reaction in egg yolk emulsion and this did 
not give a strong reaction in the plate assay. This isolate appeared to give a better 
production of lecithinase in TSB than PWB. Overall, the results suggest that most B. 
cepacia isolates do not produce lecithinase in broth culture.
Phospholipase C production
Sixteen isolates of B. cepacia were tested for phospholipase C activity in TSB and the 
results are shown in Table 15.
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Table 15
Phospholipase C activity in broth culture and in comparison with plate assay
Isolate Absorbance at 
540nm
Absorbance at 
405nm
Phospholipase C 
activity 405 nm/540 
nm
Lecithinase 
production in plate 
assay
1 0.749 0.061 0.080 +
2 0.932 0.101 0.110 +
3 0.540 0.071 0.132 +
4 0.740 0.072 0.100 +
5 0.485 0.078 0.200 +
6 0.337 0.069 0.210 +
7 0.205 0.065 0.320 +
8 0.575 0.070 0.122 +
9 0.359 0.071 0.200 +
10 0.658 0.090 0.140 ++
11 0.686 0.075 0.110 -
12 0.150 0.068 0.500 -
13 0.443 0.063 0.140 -
14 0.672 0.055 0.080 -
15 0.235 0.069 0.200 -
16 0.174 0.069 0.400 -
There was little correlation between phospholipase C production in broth culture and 
lecithinase production in the plate assay. The plate positive isolates gave readings for 
phospholipase C activity which were just as low as the plate negative isolates 
including one which gave a strong (+ +) reaction. The highest reading for 
phospholipase C activity was found with a plate negative isolate but this may have—  
been due to pigment production which can effect the results of this assay.
Protease production 
Preparation of standard curve
Table 16 shows the increase in absorbancy due to the release of azo dye from 
azocasein with increasing trypsin concentration. The standard curve is illustrated in 
Figure 8.
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Table 16
Protease activity of trypsin
Concentration of trypsin pg/ml Absorbance reading at 420nm Average
0 0.120 0.003 0.008
5 0.164 0.162 0.163
10 0.179 0.181 0.180
15 0.193 0.185 0.189
20 0.196 0.201 0.199
25 0.218 0.201 0.210
30 0.211 0.212 0.212
Figure 8
Standard curve of trypsin concentrations
0.25
0.2
0.15
0.1
0.05
Protease production in broth cuture
The protease activities of three clinical isolates of B. cepacia in TSB and PWB and in 
comparison with plate assay results are shown in Table 17.
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Table 17
Protease activity of three isolates of B, cepacia in broth culture
Isolate Plate assay Conditions Absorbance 420 run
842 ++ PW 30"C 0.051
TSB SO^ C 0.039
PW 30"C 0.016
TSB 30"C 0.029
1270 + PW 30°C 0.018
TSB 30°C 0.022
PW 30°C 0.012
TSB 30"C 0.054
1182 PW 30“C 0.013
TSB 30“C 0.023
PW 30“C 0.010
TSB 30”C 0.023
The absorbance readings of the clinical isolates were too low to be read off the 
standard curve. The absorbances for the clinical isolates were generally nearer to that 
of the protease assay buffer blank which suggests that there may be no proteolytic 
activity in B. cepacia isolates grown in broth culture.
In summary, no extracellular enzymes which may be associated with virulence, were 
detected in CF isolates of B .cepacia.
3.5.2. Haemolytic activity and serum sensitivity
A panel of 116 isolates of B. cepacia including the controls NCTC 10661, the UK 
epidemic strain CF 5610 and two environmental isolates were tested for haemolytic 
activity and serum sensitivity. Some representatives of serum sensitive and resistant 
isolates were also examined for presence of LPS.
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Haemolvsin production
The volume of packed red blood cells required in peptone water agar was determined 
in Table 18 
Table 18
Estimation of packed cell volume from various species after centrifugation
Source of 
blood
Volume of 
whole blood in 
ampoule (ml)
Volume of 
packed cells in 
ampoule (ml)
(%)
Concentration 
of blood in 
plates
Total of whole 
blood (ml) 
required.
Rabbit 2.0 1.0 5.0 10
Fowl 2.0 0.8 5.0 12.5
Sheep 2.0 1.4 5.0 7.14
Horse 2.0 0.8 7.0 17.5
Human “0 ” 2.0 0.4 5.0 25.0
pw = peptone water 
Plate assav
Before testing the panel of 116 isolates, 12 representative isolates were tested on all 
five media to evaluate use of the different blood types and incubation times. These 
results are shown in Table 19 and illustrated in Figure 9.
68
Table 19
Haemolytic activity of 12 representative isolates of B, cepacia on blood from 
different species
Isolate Days Fowl Rabbit Sheep Horse Human
1 2 ; : ; ; ;
3 -  -  -  +  -
4  -  -  +  + + +
5 -  + +  I I I I
2  1 : : ; ; ;
3 -  -
_____________________ 5_____________ -____________ -_________________-______________ -________________- ________________
2  2 : : ; ; ;-i . .
4  . . .
5  .  .  +/ -
A  2  -  -  . . .
^  3  . . . + / .  .
4  .  -  4- I I I
5  -  + +  l i l t
< I : : : : :
3 _
_____________________ 5_____________2____________ : _________________: ______________ : ________________: ________________
6  I : : : : :
4  -  -  -  + /-
5 -  -  -  + /-
7
1 -  -  -
2  -  -  -
3 -  -  -
4  -  -  -  + /-
5 -  -  -  + /-
8
10
11
1 -
2  -  -  +  + / -
3  -  -  -  + +  + +
4  -  -  I I i *f++
5 -  -  -  I I I I 1 I +
1 -  -  -  -  -
2  -  _ +  + /-
3  -  -  -  + +  + +
4  -  -  I I 1 I I I
5  -  -  -  I I I I + + +
1 2  ; ; ; _ : ;  :
4  -  -  + / -  + /-
5 -  -  +  +  -H-
These results highlight the importance of a five-day incubation period in order to 
determine haemolytic activity on blood agar plates. They also show that only horse 
and human blood cells were suitable for determining haemolysin production in B. 
cepacia. There were however some discrepancies between the results for horse and 
human cells and as a consequence the panel was tested on both horse and human 
blood agar plates.
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Figure 9 Isolates of B cepacia showing strong, 
weak and no haemolysis on human blood agar.
Haemolvsin production in broth culture
Six isolates which had given strong, medium and no haemolysis on the blood plates, 
were tested for haemolysin production in broth culture. None of them gave a reaction 
comparable to the positive control with any of the dilutions used. Where slight 
precipitation of the red blood cells appeared, this could not be correlated with the 
plate haemolysis result.
Serum sensitivity
Before examining the panel of B. cepacia isolates for their sensitivity to NHS, five 
isolates were selected to determine the optimum dilution of broth culture and 
incubation time. Bacterial growth was graded as confluent (CF), semi-confluent 
(SCF), ++ (>50 colonies), + (between 20 and 50 colonies) and +/- (<20 colonies). The 
results of the bactericidal action of normal human serum (NHS) are shown in Table 20 
and illustrated in Figure 10. Control wells of culture and HBSS were also included.
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Table 20
Growth of B, cepacia after incubation with NHS and HBSS
Isolate Time
(h)
Dilutions
10^ 10^ 10^ 10*
1 CF 0 CF CF CF SCF R
3 NHS CF CF SCF ++
HBSS CF CF SCF ++
6 NHS CF CF SCF ++
HBSS CF CF SCF ++
2CF 0 CF CF SCF SCF R
3 NHS SCF SCF ++ ++
HBSS SCF SCF ++ ++
6 NHS SCF SCF ++ ++
HBSS SCF SCF ++ ++
3CF 0 CF CF SCF SCF
3 NHS CF CF SCF SCF R
HBSS CF CF SCF SCF
6 NHS SCF SCF ++ ++
HBSS SCF SCF ++ ++
4CF 0 CF CF SCF SCF
3 NHS +/- - - S
HBSS SCF SCF SCF ++
6 NHS +/- - - -
HBSS SCF SCF ++ ++
5 0 CF CF SCF SCF s
Epidemic
CF
3 NHS +/-^ - -
HBSS CF SCF ++ + -  -  -  -
6 NHS - - - -
HBSS SCF SCF ++ ++
SS: Serum sensitivity 
R: Resistant 
S: Sensitive
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Figure 10 Growth of CF B. cepacia isolates on 
NA plates after incubation with NHS (above) and 
HBSS (below). All samples diluted 10-1 to 10- 
4.Upper left; resistant isolate, upper right; 
intermediate sensitivity, below left; sensitive 
isolate.
Table 20 shows that the first three isolates were serum resistant and the last two were 
sensitive. There appeared to be little difference between initial bacterial counts and 
after incubation with HBSS for 3 h. There was also little advantage in incubating for 6 
h. The panel of 116 CF isolates and four controls were therefore diluted 1 in 100 
which seemed to be the optimum dilution and incubated with NHS and HBSS for 3 h. 
Isolates varied from completely resistant where there was little or no difference 
between growth after incubation with serum and HBSS, to serum sensitive where the 
decrease in growth was by more than three grades for example from CL to + or +/-. 
There were also some isolates that demonstrated intermediate sensitivity where the
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decrease in growth was only by one or two grades for example from CL to SCL or ++. 
Serum sensitivity after serum incubation with LPS
To determine whether LPS from a serum sensitive isolate blocked the bactericidal 
action of serum, isolates of serum sensitive B. cepacia were incubated with NHS as in 
the previous section and the results compared with the same isolates pre-incubated 
with homologous LPS. A representative panel of 12 isolates was first tested with and 
without homologous LPS to evaluate the experiment and these results are shown in 
Table 21.
Table 21
Serum sensitivity of B, cepacia isolates with and without LPS
1 2 3 4 5 6 7 8 9 10 11 12
A CF CF CF CF CF CF CF CF CF CF CF SCF
B - :4V-' - +!- 4- : +/- 4- - 4-/-^ 4" : - 4-
C - SCF CF 4-4- 4 - r CF 4-4- 4-/-^ +/-^ 4- 4- 4-/.1
D - - - - 4- : — 4-/- - 4-/-^ 4-Z-4 : - -h
E - -
A: HBSS and culture (Control)
B: NHS and culture
C: NHS and LPS (culture added after 3h)
D: HBSS and NHS (culture added after 3h) (Control)
E; HBSS and LPS (culture added after 3h) (Control)
The columns highlighted are the serum sensitive isolates which became resistant or 
intermediate in susceptibility to serum killing after incubation with LPS, suggesting 
that LPS is the target for the serum killing reaction. The non-highlighted isolates in 
Table 21 presumably have a different serum target site. Why the HBSS and LPS in 
control row E should have a bactericidal effect is not clear.
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A summary of the results of haemolytic activity, serum sensitivity and blocking of 
serum sensitivity by LPS for 116 CF isolates and controls, is shown in Table 22.
Table 22 Comparison of haemolytic activity and serum resistance in 116 CF 
isolates of B, cepacia and controls
Control isolates CF isolates
Test NCTC
10661
Environ. 1 Environ. 2 CF 5610 77 non­
epidemic 
B. cepacia
39
epidemic 
B. cepacia
HA - - - + 16 16
SR + + + - 54 4
SI - - - - 4 26
SS - - - + 19 9
SSbl NA NA NA - 17 0
HA: Haemolysin production
SR: Serum resistant
SI: Intermediate sensitivity
SS: Serum sensitivity
SSbl: Serum sensitivity blocked by LPS
Statistical analysis indicated a significant relationship between isolates of the UK 
epidemic strain and both haemolytic activity (x  ^= 33.18; P = 0.1%) and serum 
sensitivity = 9.57; P = 1.0%).
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Detection of lipopolvsaccharide by SDS-PAGE
The results in Table 22 show that both the UK epidemic and other CF B. cepacia 
isolates may be serum resistant or sensitive. Furthermore, the sensitive non-epidemic 
isolates can be grouped into those which become resistant after blocking by LPS and 
those which remain sensitive. It was interesting to find four resistant UK epidemic 
isolates as this strain has been described as constitutively lacking the 0-side chain 
(Butler, unpublished).
To analyse fiirther the role of LPS in serum sensitivity, LPS extracts prepared in 
section 2.7.2 fi-om 14 isolates were selected and included serum sensitive and resistant 
isolates fi’om UK epidemic and other CF isolates. Volumes of 10,15 and 20 pi were 
run on SDS-PAGE gels and the results are shown in Table 23 and the banding 
patterns of 12 of the isolates are illustrated in Figure 11.
Table 23
Presence of O-side chain in serum sensitive and resistant B, cepacia isolates
Isolate Serum
sensitivity
Resistant after 
blocking by LPS
Presence of O-side 
chain
UK epidemic s _______
strain (CF 5610) 
UK epidemic R na +
UK epidemic R na + -----
UK epidemic R na +
UK epidemic R na +
UK epidemic S - -
(NCTC 10661) R na +
CF S + +
CF R na +
CF R na +
CF S + +
CF S - +
CF S - 4-
CF s - -
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1 2 3 8 9 10 11 12
Figure 11 SDS-PAGE of LPS extracts of&  cepacia isolates Lane 1 epidemic rough, 2 to 5 
epidemic smooth, 6 epidemic rough, 7 to 11 non-epidemic smooth, 12 non-epidemic rough
The volume of LPS extract found to give the clearest bands was 20 pi. The results in 
Table 23 and Figure 11 suggest that in terms of presence or absence of O-side chain 
and sensitivity or resistance to NHS, four categories of B. cepacia could be identified: 
1) isolates with an O-side chain which were serum resistant, 2) serum sensitive 
isolates with O-side chain, which became resistant after blocking with homologous 
LPS, or 3) which remained sensitive and 4) serum sensitive isolates lacking an O-side 
chain. Figure 11 shows the presence of 0-side-chains in LPS extracts of four serum 
resistant UK epidemic isolates. Lanes 7 and 9 do not show the LPS bands clearly but 
these were found to be present on repeat testing.
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3.5.3. Onion maceration assay
Onion maceration and discolouration after inoculation with B. cepacia is shown in 
Table 24.
Table 24
Onion appearance and isolation of B. cepacia
Genomovar Onion appearance after 48h Growth on selective 
media
Saline No change-no discolouration or 
softness.
-
I/IV Slightly brown but not soft +
n No change +
nia Slightly yellow and soft +
nia Slightly yellow and soft +
nia epidemic No change +/-
nib Slight discolouration +
nib No change +
nib epidemic Slightly brown but not soft -
me Slightly yellow and soft +
me No change +
me epidemic Slightly yellow and soft -
I/IV Brown discolouration but only slightly 
soft.
+
I/V Slightly yellow, not soft +
Environmental I No change +
Environmental n Very brown and soft +
NCTC 10661 1 Yellow and soft +
Epi5610m Slightly soft but no discolouration +
P. aeruginosa Brown and soft + *
* Kings agar
Only one of the two environmental isolates tested caused significant maceration of the 
onion tissue, the other isolate appeared to have no effect.
The clinical isolates showed varying degrees of discolouration and maceration but 
none of them were comparable with the environmental isolate. Interestingly, the UK 
epidemic strain isolates had little effect on the onion tissue and were the only isolates
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which could not be grown from the onion tissue after incubation. Figure 12 illustrates 
the difference between onion maceration due to environmental isolate 11 and a clinical
isolate.
Figure 12 Maceration of onion 
tissue after inoculation of an 
environmental B, cepacia 
isolate (left).
No effect after inoculation with 
a CF isolate of B. cepacia 
(right).
Summary of results
Appendix 4 shows a summary table of the biochemical and epidemiological properties 
of CF isolates identified as B. cepacia.
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4. Discussion
B. cepacia is not as common a cause of lung infections in CF patients as P. 
aeruginosa but it is associated with a more serious disease and in some cases a rapidly 
fatal outcome. Consequently, investigations into the isolation and accurate 
identfication of the organism, its source and epidemiology, and putative virulence 
factors have become very important areas of investigation.
Culturing sputum from the CF lung on to the colistin-containing selective media 
Pseudomonas cepacia (PC) agar (Gilligan et al 1985) and Oxidation-fermentation- 
lactose-polymyxin B (OFPBL) agar (Welch et al 1987), has greatly improved the 
isolation of the slowly growing B. cepacia in mixed flora specimens. However, 
Hutchinson et al (1996) found that although 24 of 35 nebulizer circuits from CF 
patients were contaminated with colistin- resistant gram-negative rods, only three of 
the isolates growing on the PC selective agar were subsequently identified as B. 
cepacia. At least 15 other species including S. maltophilia and Pseudomonas, 
Acinetobacter and Alcaligenes spp. grew on the selective medium. In this study, 
assacharolytic organisms isolated on PC agar from an environmental source were 
^Yohdhly Alcaligenes species. Of the test isolates received in LHI, 68 of 177 were not 
B. cepacia or closely related species, but had either grown on selective media or were 
colony picks from non-selective media. As many of these were colonisers of the CF 
lung, this highlights the importance of not only using selective media but also of 
employing accurate identification methods.
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However, difficulties may be encountered in distinguishing between B. cepacia and 
other Burkholderia species and gram-negative rods that grow on the selective media 
(Burdge et al 1995) and in identifying assacharolytic variants. Between the years 1965 
to 1984,4840 isolates of gram-negative non-fermentative bacteria were submitted to 
the National Collection of Type Cultures (NCTC) for identification (Holmes 1986).
Of these, 195 isolates (4%) were identified as B. cepacia which suggests that the 
organism is not uncommon in clinical material but that some laboratories have 
difficulty in identifying it. Kiska et al (1996) found that three out of four commercial 
kits incorrectly identified B. gladioli, R. pickettii and some other gram-negative rods 
as B. cepacia. The kits also failed to identify B. cepacia in some instances. In this 
study, API 20NE kits were employed in the first instance but failed to identify 
asaccharolytic isolates or distinguish between B. cepacia and B. gladioli which agrees 
with the findings of Simpson et al (1994). However van Pelt et al (1999), found that 
API 20NE gave the most accurate identification of B. cepacia although it was not 
apparent whether they used B. gladioli as a negative control. Recently developed 
genotypic methods of identification have the advantage of more rapid turnaround 
times and greater sensitivity and specificity. O'Callaghan et al (1994) exploited highly 
variable regions within the 16S rRNA for the identification of various gram-negative 
rods including B. cepacia. Although the PCR identification of B. cepacia was 
sensitive and specific in so far as the species tested, B. gladioli was not used as a 
negative control. This study revealed that a product band was formed with B. gladioli. 
Similar findings have since been reported by van Pelt et al (1999). Campbell et al 
(1995) also designed primers directed at variable 16S rRNA sequences and Tyler et al 
(1995) examined B. cepacia specific 23 S rRNA sequences and B. gladioli specific 
ITS sequences. This study found both the 16S rRNA and 23 S rRNA B. cepacia
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primers to be sensitive in identifying all isolates including asaccharolytic variants and 
a batch of isolates biochemically identified as B. gladioli. In contrast, van Pelt, et al 
(1999) found that the 23S rRNA primers lacked sensitivity and only identified 22 of 
25 B. cepacia isolates. In this study B. gladioli ITS primers failed to produce a band 
with one of the reference strains but gave positive reactions for three isolates 
identified as B. cepacia by API 20NE. With regards to specificity, all three primer 
pairs gave negative results for other gram-negative rods of clinical significance 
including the closely related R. pickettii. However, other Burkholderia species tested 
produced a band with one or more of the three primer pairs, although only B. 
vietnamiensis (out of the species tested here) has been linked to human disease. 
Vandamme et al (1997) concluded that B. cepacia comprises at least five different 
species or genomovars including B. vietnamiensis and named this the B. cepacia 
complex. Their results showed that the majority of CF isolates could be placed in 
genomovar II or III but few in genomovar I, IV or B. vietnamiensis. This agrees with 
the results of the present study where out of 116 isolates, 48 and 58 were 
biochemically classified in genomovars II and III respectively while only nine could 
be classified in genomovars I/IV. However, in the biochemical schemes of both 
Vandamme et al (1997) and Holmes, et al (1986), there is a problem of long 
incubation times and mis-identification may occur. This may have been the reason for 
the PCR positive B. cepacia isolate which was biochemically ‘P. gladiolV (Appendix 
4) and an example of the hybrid described by Simpson et al (1994). Also, a negative 
reaction in ammonium salt sugars is inadequate for the identification of asaccharolytic 
B. cepacia without further tests. Biochemical tests therefore do not offer an advantage 
over PCR methods for identifying B. cepacia but the former can be used to classify 
the complex into genomovar groups and to identify B. vietnamiensis. A fiirther
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advantage of PCR techniques is that the differentiation of genomovar groups 
including B. vietnamiensis by PCR (Bauemfeind et al 1999), (Mahenthiralingam et al. 
2000), (LiPuma et al. 1999) and RFLP analysis of amplified 16S rDNA (Segonds et al 
1999) has recently been described.
PCR identification of B. cepacia and other CF pathogens may be applied directly to 
clinical specimens, hence minimising the need for growth and isolation. Karpati and 
Jonasson (1996), found by using one species specific and one universal primer that 
PCR detection of P. aeruginosa in sputum was 93% sensitive but detection of R 
cepacia was only 78% sensitive. In contrast, O'Callaghan et al (1994) found that non­
specific PCR products were produced with their 16S rRNA primers on sputum 
specimens which had been solubilised by dithiothreitol. They concluded that further 
purification of specimens may be necessary. In this study, 32 of 35 sputum specimens 
from B. cepacia positive CF patients were positive in the PCR using the 16S rRNA 
primers described by Campbell et al (1995). Two of the three which were PCR 
negative were culture-positive for other gram-negative rods and the third was culture- 
negative. Furthermore, exactly one half of the PCR positive sputa were culture- 
negative suggesting a high degree of sensitivity as well as specificity which agrees 
with the findings of Whitby et al (1998).
B. cepacia is both an environmental and a clinical pathogen and consequently 
determining the source of the organism in human infections is a cause for concern. 
This has recently been highlighted by the proposed use of B. cepacia os a biopesticide 
(Govan and Vandamme 1998). There are four possible routes of colonisation: i) 
directly from environmental isolates in the natural environment, ii) indirectly via
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contaminated equipment or solutions, iii) directly from another patient, iv) indirectly 
from an environment contaminated Avith patient isolates.
Contrary to popular belief, B. cepacia is sparse in the natural environment with few 
reported isolations (Butler, et al 1995), (Honicky, et al 1993). In this study, B. cepacia 
could not be isolated from samples taken from environmental sites which included 
soil, water and vegetation. It has been suggested that environmental and clinical 
isolates of B. cepacia differ in their plant pathogenic capacity (Tabacchioni et al
1995), (Bevivino, et al 1994), including their ability to macerate onion tissue 
(Gonzalez and Vidaver 1979). This study found only one isolate capable of causing 
significant maceration of onion tissue and this was from an environmental source. In 
contrast, Butler et al (1995), despite concluding that none of their environmental 
isolates had phenotypic properties equivalent to the UK CF epidemic strain, found that 
this strain could nevertheless cause soft rot in onions. There is however evidence that 
environmental isolates can cause human disease and have been associated with a type 
of inflammation and maceration of the toe-webs of troops training in swamps (Taplin, 
et al 1971). Gonzalez and Vidaver (1979) found that both plant and clinical isolates 
were toxic for mice and had similar antibiotic sensitivities. Furthermore, LPS from 
both clinical and environmental isolates has been reported to have greater endotoxic 
activity than LPS from P. aeruginosa (Hughes et al 1997), (Shaw, Poxton et al 1995).
The presence of B. cepacia in the immediate environment of colonised CF patients 
would suggest that these patients were the source of the organism and that this posed a 
risk to others. However B. cepacia does not appear to be more abundant in the homes 
of colonised patients than in control homes (Mortensen et al 1995) and only sparsely 
contaminated a CF ward with no carriage by staff or patients (Doring et al 1997).
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Nelson et al (1991) found that colonised CF patients in hospital did contaminate their 
environment but that this was minimal and the risk of indirect carriage from the 
environment subsequently low. In contrast, medical equipment and contaminated 
antiseptic solutions do appear to be potential sources of B. cepacia infection in CF and 
non-CF patients (Ederer and Matsen 1972), (Berkelman et al 1982), (Gravel-Tropper 
et al 1996), (Hutchinson et al 1996), (Reboli et al 1996), (Noriega et al 1975), (Smith 
et al 1985), (Gefric et al 1979), (Speller et al 1971), (Bassett et al 1973) (Hobson et al
1995).
The possibility of patient-to-patient transmission of B. cepacia is an emotive issue as 
colonised CF patients are often treated on separate wards and advised to avoid social 
contact with non-colonised patients. Some would argue that cross-infection is not a 
problem as many patients have sporadic isolates (Steinbach et al 1994) and even if a 
particular strain is common in a hospital, this may not be due to direct patient to 
patient spread as some patients do not acquire the strain despite close contact with 
carriers (Segonds et al 1997), (LiPuma et al 1988), (Taylor et al 1992). However, a 
strain common to more that one centre is strongly indicative of patient-to-patient 
transmission by hospital transfer or social contact (Govan et al 1993), (Pitt et al
1996), (Segonds et al 1997) (Smith et al 1993), (Smyth et al 1993). Furthermore, a 
reduction in the incidence of B. cepacia colonisation and the absence of endemic 
strains in hospitals where carriers are segregated has been supported (Paul et al 1998), 
(Thomassen et al 1986). There is now strong evidence for the presence of a strain of 
B. cepacia capable of causing epidemic spread in the UK CF population within and 
between hospitals and in the social context (Govan et al 1993), (Pitt et al 1996), 
(Simpson et al 1994). This has been variously described as ribotype 1 (Pitt et al 1996)
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and ET 12 (Johnson et al 1994) depending on the fingerprinting method employed and 
was assigned to genomovar III by Vandamme et al (1997). It is not known why 
particular strains have the potential to cause epidemic spread whilst others are 
confined to single cases or a few patients in close contact, although, in recent years 
various “epidemic” markers have been described which are associated with these 
strains. The most well known of these is the cblA gene encoding long intertwined 
cable-like pili which, unlike the other pilin structures in B. cepacia, appear to be 
associated with optimal colonisation of the CF lung enhancing epidemic spread 
(Sajjan et al 1995), Goldstein et al (1995). Sun et al (1995) found that the PFGE and 
ribotype profiles of c6M-positve isolates involved in an outbreak in Toronto, were not 
only indistinguishable from one another but also from the UK epidemic strain. Tyler, 
et al (1996) looked for an association between the presence of insertion sequence (IS) 
elements, cblA, electrophoretic type (ET) and ribotype (RT) in isolates of B. cepacia. 
An IS hybrid of IS iiJd  inserted within IS402 was found exclusively in the epidemic 
strain from Ontario and the UK, being detected in approximately 95% of isolates. It is 
not known whether the hybrid is linked to the apparent increase in transmissibility and 
virulence of this strain or whether it is simply a marker for the lineage. 
Mahenthiralingam et al (1996), identified a conserved region in seven epidemic R 
cepacia strains (BCESM) including one c6M-positive isolate. They suggested that the 
presence of this marker was related to a strain’s ability to infect multiple patients and 
become epidemic. In this study, all the control isolates which were indistinguishable 
from the UK epidemic strain by RAPD, were positive for all three epidemic markers 
and those from smaller clusters and sporadic isolates were negative for cblA and the IS 
hybrid but four of five were positive for BCESM. However looking at the results of 
the CF test isolates, it appears that only the UK epidemic strain is widespread in the
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UK and was found in 13 hospitals. BCESM was present in all these isolates but was 
absent in four smaller clusters although present in a minority of sporadic isolates. The 
IS hybrid and cblA were exclusive to the UK epidemic strain but whereas cblA was 
present in all isolates, the IS hybrid was missing in a minority. All isolates of the 
epidemic strain apart from one were biochemically classifed as genomovar III.
Despite much research, little is known about the virulence factors of B. cepacia and 
why the outcome in CF patients colonised with the same strain can vary from 
asymptomatic carriage to a rapidly fatal necrotising pneumonia. For most pathogenic 
bacteria apart from some exotoxin producers, colonisation and avoidance of host 
defences is of paramount importance in the disease process. Adherence to host tissues 
is often the the first step and is particularly important in the lung to avoid the innate 
immune response of muco-ciliary clearance (albeit impaired in CF patients). Many 
bacterial species produce polar or peritrichous fimbriae which attach to specific 
receptors on host surfaces. Fimbriated B. cepacia display a much higher level of 
adherence to mucosal surfaces than non-fimbriated and this has been linked to a 
poorer prognosis (Sajjan et al 1992). B. cepacia has also been shown to invade and 
sequest in epithelial cells where it may be protected from host immune responses and 
antibiotics (Bums et al 1996), (Tipper et al 1998).
Many bacteria also avoid active immune responses by protecting themselves with an 
outer capsule or slime layer such as the alginate polysacchharide of P. aeruginosa. 
Gram-negative bacteria may also be protected by the long oligosaccharide side-chains 
of LPS which hinder the insertion of the complement mediated membrane attack 
complex. P. aeruginosa isolated from the CF lung are most often deficient in 0-side-
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chains and are serum sensitive. However, Butler et al (1994) found that even though 
all rough LPS isolates of B. cepacia were serum sensitive or intermediate, smooth 
LPS isolates may also be sensitive suggesting that factors other than the presence of 
an O side-chain may be important. This study also found that all rough isolates of B. 
cepacia were serum sensitive or intermediate but four isolates of the UK epidemic 
strain were shown to possess O-side chains and were serum resistant. This contrasts 
with the statement of Butler et al (1994) that this strain is always rough. However the 
relationship between serum sensitivity and epidemic or non-epidemic isolates was 
shown to be significant. Smooth LPS isolates in this study were either serum sensitive 
or resistant and furthermore, sensitive smooth LPS isolates either remained sensitive 
or became resistant after serum blocking with homologous LPS. This supports the 
theory that factors other than LPS may be involved in serum resistance. The only 
significance of genomovar grouping with regards to serum sensitivity is that 
genomovar III has all the UK epidemic isolates so that the majority of this group are 
sensitive or intermediate.
Enzymes produced by bacterial species are theoretically toxins in that their substrate is 
invariably host tissue. However, a link with disease or even minor tissue damage 
cannot always be demonstrated. In this study, some B. cepacia were shown to be 
strong producers of enzymes such as haemolysin, protease and lecithinase and these 
were mainly non-epidemic genomovar Ilia isolates. In contrast, genomovar II and IIIc 
isolates (including the UK epidemic strain) were mainly poor enzyme producers and 
this characteristic varied in genomovars I/IV. With few exceptions, none of the 
enzymes detected in plate assays were produced extracellularly in broth culture. 
Approximately 30% of isolates in this study gave zones of lysis on human blood agar
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after five days incubation. Haemolysis was comparable on horse blood agar but there 
was little activity on fowl, rabbit or sheep blood cells in agar. These results are 
contrary to those of Nakazawa et al (1987), Gessner and Mortensen (1990) and 
McKevitt and Woods (1984), who all found that only about 4% of R cepacia isolates 
produced lysis on any blood agar. However, each of the groups incubated the blood 
agar plates for approximately 48 h which highlights the importance of a five day 
incubation period as employed here. As with serum sensitivity, the relationship 
between epidemic isolates and haemolysis was statistically significant. One problem 
which this study encountered was diffusion of the melanin-like pigment of the UK 
epidemic strain into the blood agar making interpretation difficult in some cases.
Approximately 50% of isolates studied here produced lecithinase (phospholipase C) 
on egg yolk agar plates and these were randomly distributed throughout the 
genomovars, although less in IIIc. There was more activity on tween 20 and 80 plates 
than on egg yolk agar although Gessner and Mortensen (1990) found that most 
isolates produced both enzymes. Lonon et al (1988), also found that phospholipase C 
was not produced in broth culture and that lipase activity on tween plates was 
unrelated to phospholipase C activity. The role of R  cepacia lipase in pathogenicity is 
unclear although Straus et al (1992) showed that phagocytosis of the organism was 
reduced in the presence of lipase.
In this study 31% of isolates, mainly from genomovars Ilia and I/IV produced a 
proteolytic reaction on casein agar. B. cepacia does not produce the potent exotoxins 
and elastase enzymes equivalent to those of P. aeruginosa although McKevitt et al 
(1989) described an extracellular proteinase which was antigenically similar to P.
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aeruginosa elastase in culture supernatants of B. cepacia. This could explain the 
systemic spread of low doses of P. aeruginosa in the burned mouse model in 
comparison with localised higher inocula of other Pseudomonas species including B. 
cepacia (Stover et al 1983). In the CF lung, however, the opposite situation is seen 
whereby P. aeruginosa remains localised whilst B. cepacia is capable of systemic 
spread. The factors involved in this seemingly paradoxical situation are not known 
and it is important to note that isolates of genomovar Hie, which are devoid of 
detectable enzyme activity, have nevertheless been associated with fatal disease in CF 
patients (Wilsher et al 1997), (Clode et al 1999). Other possible pathogenic 
mechanisms not investigated in this study are the ability to invade cells, avoid host 
defence mechanisms, the tissue damaging action of endotoxin, siderophore production 
and antibiotic resistance.
In conclusion, this study has shown that PCR methods for the identification of B. 
cepacia are more sensitive, specific and time saving than traditional biochemical and 
kit methods. They also allow for the detection of the organism directly in clinical 
specimens hence eliminating the need for selective media. The classification of B. 
cepacia and related species into genomovar groups has caused much speculation 
about the association of epidemic and virulent strains with particular genomovars.
This is largely unsupported by published data other than the association of the UK 
epidemic strain and some smaller clusters of multiply antibiotic resistant strains 
(Simpson et al 1994) with genomovar III (Vandamme et al 1997). This study found 
that only the UK epidemic strain is widespread in the UK and that it is most reliably 
identified by the detection of the chlA gene. The presence of intracellular enzymes in 
B. cepacia may have some correlation with genomovar group but the possible role of
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these enzymes in pathogenicity is uncertain and these and other virulence factors 
would have to be correlated with clinical condition in a future study.
90
5. References
Achouak, W., R. Christen, et al. (1999). '^Burkholderia caribensis sp. nov., an 
exopolysaccharide-producing bacterium isolated from vertisol microaggregates in 
Martinique.” International Journal of Systematic Bacteriology 49: 787-794.
Anderson, R., R. Vess, etal. (1991). “Investigations of intrinsic Pseudomonas cepacia 
contamination in commercially manufactured povidone-iodine.” Infection Control and 
Hospital Epidemiology 12: 297-302.
Ballard, R., N. Palleroni, et al. (1970). “Taxonomy of the aerobic Pseudomonads: 
Pseudomonas cepacia, P. marginata, P. alliicola and P. caryophylli.^' Journal of 
General Microbiology 60: 199-214.
Ballestero, S., I. Virseda, et al. (1995). "Stenotrophomonas maltophilia in cystic 
fibrosis patients.” European Journal of Microbiology and Infectious Diseases 14: 728- 
729.
Bassett, D., J. Dickson, et al. (1973). “Infection of bolter valve hy Pseudomonas- 
contaminated chlorhexidine.” Lancet 1: 1263-1264.
Bauemfeind, A., I. Schneider, et al. (1999). “Discrimination of Burkholderia 
multivorans and Burkholderia vietnamiensis from Burkholderia cepacia Genomovars 
I, III and IV by PCR.” Journal of Clinical Microbiology 37: 1335-1339.
91
Beckman, W. and T. Lessie (1979). “Response of Pseudomonas cepacia to B-lactam 
antibiotics: utilization of Penicillin G as the carbon source.” Journal of Bacteriology 
140: 1126-1128.
Berka, R., G. Gray, et al. (1981). “Studies of Phospholipase C (heat-labile hemolysin) 
in Pseudomonas aeruginosaP Infection and Immunity 34 : 1071-1074.
Berkelman, R., J. Godley, et al. (1982). ^^Pseudomonas cepacia peritonitis associated 
with contamination of automatic peritoneal dialysis machines.” Annals of Internal 
Medicine 96: 456-458.
Bevivino, A., S. Tabacchioni, et al. (1994). “Phenotypic comparison between 
rhizosphere and clinical isolates of Burkholderia cepacia.^' Microbiology 140: 1069- 
1077.
Brett, P. J., D. DeShazer, et al. (1998). "^Burkholderia thailandensis sp. nov., a 
Burkholderia pseudomallei-liks species.” International Journal of Systematic 
Bacteriology 48: 317-320.
Briat, J.-F. (1992). “Iron assimilation and storage in prokaryotes.” Journal of General 
Microbiology 138: 2475-2483.
Burdge, D., E. Nakielna, et al. (1993). “Case-control and yector studies of nosocomial 
acquisition of Pseudomonas cepacia in adult patients with cystic fibrosis.” Infection 
Control and Hospital Epidemiology 14: 127-130.
92
Burdge, D., M. Noble, et al. (1995). ""Xanthomonas maltophilia misidentified as 
Pseudomonas cepacia in cultures of sputum from patients with cystic fibrosis: a 
diagnostic pitfall with major clinical implications.” Clinical Infectious Diseases 20: 
445-448.
Burkholder, W. (1950). Sour skin: A bacterial rot of onion bulbs. Phytopathology 40: 
115-117.
Bums, J., C. Wadsworth, et al. (1992). Characterisation of inyasion of respiratory 
epithelium by Pseudomonas cepacia, abstr. 201, p. 289 In Proceedings of the sixth 
Annual North American Cystic Fibrosis Conference, Wiley-Liss, New York.
Bums, J. L., J. Mechthild, et al. (1996). Inyasion of respiratory epithelial cells by 
Burkholderia (Pseudomonas) cepacia. Infection and Immunity 64: 4054-4059.
Butler, S., C. Doherty, et al. (1995). Burkholderia cepacia and cystic fibrosis: Do 
natural enyironments present a potential hazard? Joumal of Clinical Microbiology 33: 
1001-1004.
Butler, S. L., J. W. Nelson, et al. (1994). Semm sensitiyity of Burkholderia 
(Pseudomonas) cepacia isolates from patients with cystic fibrosis. FEMS 
Immunology and Medical Microbiology 8: 285-292.
Campbell, P. W., J. A. Phillips, et al. (1995). Detection of Pseudomonas 
(Burkholderia) cepacia using PCR. Pediatric Pulmonology 20: 44-49.
93
Cheng, H. and T. Lessie (1994). Multiple replicons constituting the genome of 
Pseudomonas cepacia 17616. Joumal of Bacteriology 176: 4034-4042.
Cimolai, N., C. Trombley, et al. (1995). Selectiye media for isolation of Burkholderia 
(Pseudomonas) cepacia from the respiratory secretions of patients with cystic fibrosis. 
Joumal of Clinical Pathology 48: 488-490.
Ciofii, O., T. Jensen, et al. (1996). Meropenem in cystic fibrosis patients infected with 
resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitiyity 
to B-lactam antibiotics. Clinical Microbiology and Infection 2: 91-98.
Clode, F. E., L. A. Metherell, et al. (1999). Nosocomial acquisition of Burkholderia 
gladioli in patients with cystic fibrosis. American Joumal of Respiratory and Critical 
Care Medicine 160: 374-375.
Coenye, T., B. Holmes, et al. (1999). Burkholderia cocovenenans (yan Damme et 
n/. 1960) Gillis et al. 1995 and Burkholderia vandii Urakami et al. 1994 are junior 
synonyms of Burkholderia gladioli (Seyerini 1913) Yabuuchi et al. 1993 and 
Burkholderia plantarii (Azegami et n/. 1987) Urakami et a/. 1994, respectiyely. 
Intemational Joumal of Systematic Bacteriology 49: 37-42.
Coenye, T., J. LiPuma, et al. (2001). Burkholderia cepacia genomoyar VI, a new 
member of the Burkholderia cepacia complex isolated from cystic fibrosis patients. 
Intemational Joumal of Systematic and Eyolutionary Microbiology 51: 271-279.
94
Dailey, R. and E. Benner (1968). Necrotizing pneumonitis due to the Pseudomonad 
"Eugonic" Oxidizer -Group 1". New England Joumal of Medicine 279: 361-362.
Darling, P., M. Chan, et al. (1998). Siderophore production by cystic fibrosis isolates 
of Burkholderia cepacia. Infection and Immunity 66: 874-877.
Dayies, K. (1991). Cystic fibrosis: the quest for a cure. New Scientist (7 December): 
30-34.
De Braekeleer, M., C. Allard, et al. (1998). Genetic determinants of Pseudomonas 
aeruginosa colonisation in cystic fibrosis patients in Canada. European Joumal of 
Clinical Microbiology and Infectious Disease 17: 269-271
Desai, M., T. Buhler, et al. (1998). Increasing resistance of planktonic and biofilm 
cultures of Burkholderia cepacia to ciprofloxacin and ceftazidime during exponential 
growth. Joumal of Antimicrobial Chemotherapy 42: 153-160.
Doring, G., S. Jansen, et al. (1997). Distribution and transmission of Pseudomonas 
aeruginosa and Burkhoderia cepacia in a hospital ward. Hospital Infection Control 
Supplement 1: 4.
Ederer, G. and J. Matsen (1972). Colonization and infection with Pseudomonas 
cepacia. Joumal of Infectious Diseases 125(6): 613-618.
95
Fiel, S. (1993). Clinical management of pulmonaiy disease in cystic fibrosis. Lancet 
341; 1070-1074.
Geftic, S., H. Heyman, et al. (1979). Fourteen-year survival of Pseudomonas cepacia 
in a salts solution preserved with benzalkonium chloride. Applied and Environmental 
Microbiology 37: 505-510.
Gessner, A. and J. Mortensen (1990). Pathogenic factors of Pseudomonas cepacia 
isolates fi*om patients with cystic fibrosis. Joumal of Medical Microbiology 33: 115- 
120.
Gilligan, P., P. Gage, et al. (1985). Isolation medium for the recovery of Pseudomonas 
cepacia fi’om respiratoiy secretions of patients with cystic fibrosis. Joumal of Clinical 
Microbiology 22: 5-8.
Gillis, M., T. Van, et al. (1995). Polyphasic taxonomy in the genus Burkholderia 
leading to an amended description of the genus and proposition of Burkholderia 
vietnamiensis sp. nov. for N2  -fixing isolates fi*om rice in Vietnam. Intemational
Joumal of Systematic Bacteriology 45: 274-289.
Goldstein, R., L. S. Ru-Zhang Jiang, et al. (1995). Stmcturally variant classes of pilus 
appendage fibers coexpressed firom Burkholderia (Pseudomonas) cepacia. Joumal of 
Bacteriology 177: 1039-1052.
96
Gonzalez, C. F. and A. K. Vidaver (1979). Bacteriocin, plasmid and pectolytic 
diversity in Pseudomonas cepacia of clinical and plant origin. Joumal of General 
Microbiology 110: 161-170.
Govan, J. and G. Harris (1985). Typing of Pseudomonas cepacia by bacteriocin 
susceptibility and production. Joumal of Clinical Microbiology 22: 490-494.
Govan, J. and P. Vandamme (1998). Agricultural and medical microbiology: a time 
for bridging gaps. Microbiology 144: 2373-2376.
Govan, J., P. H. Brown, et al. (1993). Evidence for transmission of Pseudomonas 
cepacia by social contact in cystic fibrosis. Lancet 342: 15-19.
Gravel-Tropper, D., M. Sample, et al. (1996). Three-year outbreak of 
pseudobacteremia with Burkholderia cepacia traced to a contaminated blood gas 
analyzer. Infection Control and Hospital Epidemiology 17: 737-740.
Gregory, W. and McNabb (1986). ""Pseudomonas cepacia.^' Topics in Clinical 
Microbiology 7(5): 281 -284.
Hardy, P., G. Ederer, et al. (1970). Contamination of commercially packaged urinary 
catheter kits with the Pseudomonad EO-1. New England Joumal of Medicine 282: 33- 
35.
97
Hebbar, K., M. Martel, et al. (1998). Suppression of pre- and postmergence damping- 
off in com by Burkholderia cepacia. European Joumal of Plant Pathology 104: 29-36.
Heidt, A., H. Monteil, et al. (1983). O and H serotyping of Pseudomonas cepacia. 
Joumal of Clinical Microbiology 18: 738-740.
Henry, D., M. Campbell, et al. (1997). Identification of Burkholderia cepacia isolates 
from patients with cystic fibrosis and use of a simple new selective medium. Joumal 
of Clinical Microbiology 35: 614-619
Hitchcock, P., T. Brown (1983). Morphological heterogeneity among Salmonella 
lipopolysaccharide chemotypes in silver-stained polyacrylamide gels. Joumal of 
Bacteriology 154: 269-277.
Hobson, R., I. Gould, et al. (1995). Burkholderia (Pseudomonas) cepacia as a cause 
of brain abscesses secondary to chronic suppurative otitis media. European Joumal of 
Clinical Microbiology and Infectious Diseases 14: 908-911.
Holmes, A., J. Govan, et al. (1998). Agricultural use of Burkholderia (Pseudomonas) 
cepacia: A threat to human health? Emerging Infectious Diseases 4: 221-227.
Holmes, B. (1986). The identification of Pseudomonas cepacia and its occurrence in 
clinical material. Joumal of Applied Bacteriology 61: 299-314.
98
Holmes, B., C. Pinning, et al. (1986). A Probability matrix for the identification of 
Gram-negative, aerobic, non-fermentative bacteria that grow on nutrient agar. Joumal 
of General Microbiology 132: 1827-1842.
Honicky, R., D. Harden, et al. (1993). Pseudomonas cepacia at summer camps for 
persons with cystic fibrosis. Morbidity and Mortality Weekly Report 42: 456-458.
Hughes, J., J. Stewart, et al. (1997). Priming of neutrophil respiratory burst activity by 
lipopolysaccharide fi’om Burkholderia cepacia. Infection and Immunity 65: 4281- 
4287.
Hutchinson, G., S. Parker, et al. (1996). Home-use nebulizers: a potential primary 
source of Burkholderia cepacia and other colistin resistant, Grammegative^bacteriain^ 
patients with cystic fibrosis. Joumal of Clinical Microbiology 34: 584-587.
Johnson, W., S. Tyler, et al. (1994). Linkage analysis of geographic and clinical 
clusters in Pseudomonas cepacia infections by multilocus enzyme electrophoresis and 
ribotyping. Joumal of Clinical Microbiology 32: 924-930.
Jonsson, V. (1970). Proposal of a new species Pseudomonas kingii. Intemational 
Joumal of Systematic Bacteriology 20 255-257.
Karpati, F. and J. Jonasson (1996). Polymerase chain reaction for the detection of 
Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia 
in sputum of patients with cystic fibrosis. Molecular and Cellular Probes 10: 397-403.
99
Kiska, D., A. Kerr, et al. (1996). Accuracy of four commercial systems for 
identification of Burkholderia cepacia and other gram-negative nonfermenting bacilli 
recovered fi*om patients with cystic fibrosis. Joumal of Clinical Microbiology 34: 886- 
891.
Knight, R. (1992). Genetics of cystic fibrosis. British Joumal of Hospital Medicine 
47: 502-506.
Kostman, J., T. Edlind, et al. (1992). Molecular epidemiolgy of Pseudomonas cepacia 
determined by polymerase chain reaction ribotyping. Joumal of Clinical Microbiology 
30: 2084-2087.
Kreger, A. and L. Gray (1978). Purification of Pseudomonas aeruginosa proteases and 
microscopic characterisation of pseudomonal protease-induced rabbit comeal damage. 
Infection and Immunity 19: 630-648.
Kuehn, M., K. Lent, et al. (1992). Fimbriation of Pseudomonas cepacia. Infection and 
Immunity 60: 2002-2007.
Laemmli, U. (1970). Cleavage of stmctural proteins during the assembly of the head 
of bacteriophage T4. Nature (London) 227: 680-685.
LiPuma, J., S. Dasen, et al. (1990). Person-to-person transmission of Pseudomonas 
cepacia between patients with cystic fibrosis. Lancet 336: 1094-1096.
100
LiPuma, L, B. Dulaney, et al. (1999). Development of rRNA-based PCR assays for 
identification of Burkholderia cepacia complex isolates recovered from cystic fibrosis 
patients. Joumal of Clinical Microbiology 37: 3167-3170.
LiPuma, J., J. Mortensen, et al. (1988). Ribotype analysis of Pseudomonas cepacia 
from cystic fibrosis treatment centers. Joumal of Pediatrics 113: 859-862.
Littlewood, J. (1986). An overview of the management of cystic fibrosis. Joumal of 
the Royal Society of Medicine 79: 55-63.
Lonon, M., D. Woods, et al. (1988). Production of lipase by clinical isolates of 
Pseudomonas cepacia. Joumal of Clinical Microbiology 26: 979-984.
Lu, D.-T., S.-C. Chang, et al. (1997). In vitro activities of antimicrobial agents, alone 
and in combinations, against Burkholderia cepacia isolated from blood. Diagnostic 
Microbiology and Infectious Diseases 28: 187-191.
Mahenthiralingam, E., J. Bischof, et al. (2000). DNA-based diagnostic approaches for 
identification of Burkholderia cepacia complex , Burkholderia vietnamiensis, 
Burkholderia multivorans, Burkholderia stabilis and Burkholderia cepacia 
genomovarsl and III. Joumal of Clinical Microbiology 38: 3165-3173.
101
Mahenthiralingam, E., M. E. Campbell, étal. (1996). Epidemiology oîBurkholderia 
cepacia infection in patients with cystic fibrosis: Analysis by randomly amplified 
polymorphic DNA fingerprinting. Journal of Clinical Microbiology 34: 2914-2920.
Mahenthiralingam, E., D. A. Simpson, et al. (1997). Identification and 
characterisation of a novel DNA marker associated with epidemic Burkholderia 
cepacia strains recovered fi-om patients with cystic fibrosis. Journal of Clinical 
Microbiology 35: 808-816.
Matrician, L., A. Gretchen, et al. (2000). Outbreak of nosocomial Burkholderia 
cepacia infection and colonisation associated with intrinsically contaminated 
mouthwash. Infection Control and Hospital Epidemiology 21: 739-741.
May, J. and D. Roberts (1969). Bronchial Infection in Cystic Fibrosis. The Lancet 1 
602-603
McKevitt, A., S. Bajaksouzian, et al. (1989). Purification and characterization of an 
extracellular protease from Pseudomonas cevacia. Infection and Immunity 57: 771- 
778.
McKevitt, A. and D. Woods (1984). Characterization of Pseudomonas cepacia 
isolates from patients with cystic fibrosis. Joumal of Clinical Microbiolgy 19: 291- 
293.
102
McLoughlin, T., J. Quinn, et al. (1992). Pseudomonas cepacia suppression of 
sunflower wilt fungus and role of antifungal compounds in controlling the disease. 
Applied and Environmental Microbiology 58:1760-1763.
Meyer, J., V. Van, et al. (1995). Omibactin production and transport properties in 
strains of Burkholderia vietnamiensis and Burkholderia cepacia ( formerly 
Pseudomonas cepacia). BioMetals 8: 309-317.
Meyer, J.-M., D. Hohnadel, et al. (1989). Cepabactin from Pseudomonas cepacia, a 
new type of siderophore. Joumal of General Microbiology 135:1479-1487.
Mortensen, J., M. Fisher, et al. (1995). Recovery of Pseudomonas cepacia and other 
Pseudomonas species from the environment. Infection Control and Hospital 
Epidemiology 16: 30-32.
Muhdi, K., F. Edenborough, et al. (1996). Outcome for patients colonised with 
Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an 
epidemic. Thorax 51: 374-377.
Nakamura, Y., S. Hyodo, et al. (1986). Serological classification of Pseudomonas 
cepacia by somatic antigen. Joumal of Clinical Microbiology 24: 152-154.
Nakazawa, T., Y. Yamada, et al. (1987). Characterisation of hemolysin in 
extracellular products of Pseudomonas cepacia. Joumal of Clinical Microbiology 25: 
195-198.
103
Nelson, J., C. Doherty, et al. (1991). Pseudomonas cepacia in inpatients with cystic 
fibrosis. Lancet 338: 1525.
Nelson, J. W., S. L. Butler, et al. (1994). Virulence factors of Burkholderia cepacia. 
FFMS Immunology and Medical Microbiology 8: 89-98.
Noriega, E., E. Rubinstein, et al. (1975). Subacute and acute endocarditis due to 
Pseudomonas cepacia in heroin addicts. American Joumal of Medicine 59: 29-36.
O'Callaghan, E., M. Tanner, et al. (1994). Development of a PCR probe test for 
identifying Pseudomonas aeruginosa and Pseudomonas (Burkholderia) cepacia. 
Joumal of Clinical Pathology 47: 222-226.
ONeil, K., J. Herman, et al. (1986). Pseudomonas cepacia: An emerging pathogen in 
chronic granulomatous disease. Joumal of Pediatrics 108: 940-942.
Ouchi, K., M. Abe, et al. (1995). Analysis of  strains of Burkholderia (Pseudomonas) 
cepacia isolated in a nosocomial outbreak by biochemical and genomic typing. 
Joumal of Clinical Microbiology 33: 2353-2357.
Palleroni, N., R. Kunisawa, et al. (1973). Nucleic acid homologies in the genus 
Pseudomonas. Intemational Joumal of Systematic Bacteriology 23 333-339.
104
Palleroni, N. and B. Holmes (1981). Pseudomonas cepacia sp. nov., nom. rev. 
Intemational Joumal of Systematic Bacteriology 31: 479-481.
Parke, J., A. Joy, et al. (1991). Biological control of Pythium damping-off and 
Aphanomyces root rot of peas by application of Pseudomonas cepacia or 
P.fluorescens to seed. Plant Disease 75: 987-992.
Paul, M., M. Pegler, et al. (1998). Molecular epidemiology of Burkholderia cepacia in 
two Australian cystic fibrosis centres. Joumal of Hospital Infection 38: 19-26.
Pier, G. (1998). Pseudomonas aeruginosa: a key problem in cystic fibrosis. ASM 
News 64: 339-347.
Pitcher, D., N. Saunders, et al. (1989). Rapid extraction of bacterial genomic DNA 
with guanidium thiocyanate. Letters in Applied Microbiology 8:151.
Pitt, T. L., M. E. Kaufinann, et al. (1996). Type characterisation and antibiotic 
susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patientsjMth 
cystic fibrosis in the United Kingdom and the Republic of Ireland. Joumal of Medical 
Microbiology 44: 203-210.
Rabkin, C., W. Jarvis, et al. (1989). Pseudomonas cepacia typing systems: 
Collaborative study to assess their potential in epidemiologic investigations. Reviews 
of Infectious Diseases 2: 600-607.
105
Rajyaguru, J. and M. Muszynski (1998). Sensitization of Burkholderia cepacia to 
antibiotics by cationic drugs. Joumal of Antimicrobial Chemotherapy 41: 277-280.
Rayner, R., E. Hiller, et al (1990). Haemophilus infection in cystic fibrosis. Archives 
of Disease in Childhood 65 255-258.
Reboli, A., R. Koshinski, et al. (1996). An outbreak of Burkholderia cepacia lower 
respiratory tract infection associated with contaminated albuterol nebulization solution 
Infection Control and Hospital Epidemiology 17: 741-743.
Reed, R. (1998). Community-acquired Burkholderia cepacia sepsis in children. 
Clinical Microbiology Newsletter 20: 147.
Ryley, H., L. Millar-Jones, et al. (1995). Characterisation of Burkholderia cepacia 
from cystic fibrosis patients living in Wales by PCR ribotyping. Joumal of Medical 
Microbiology 43: 436-441.
Sajjan, S. and J. Forstner (1992). Identification of the mucin-binding adhesin^f 
Pseudomonas cepacia isolated from patients with cystic fibrosis. Infection and 
Immunity 60: 1434-1440.
Sajjan, U., M. Corey, et al. (1992). Binding of Pseudomonas cepacia to normal 
human intestinal mucin and respiratory mucin from patients with cystic fibrosis. 
Joumal of Clinical Investigation 89: 648-656.
106
Sajjan, U., Y. Wu, et al (2000). Preferential adherence of cable-piliated Burkholderia 
cepacia to respiratory épithélia of CF knockout mice and human cystic fibrosis lung 
explants. Joumal of Medical Microbiology 49: 875-885.
Sajjan, U. S., L. Sun, et al. (1995). Cable (Cbl) type II pili of cystic fibrosis-associated 
Burkholderia (Pseudomonas) cepacia: Nucleotide sequence of the chlA major subunit 
pilin gene and novel morphology of the assembled appendage fibers. Joumal of 
Bacteriology 177: 1030-1038.
Samuels, S., C. Moss, et al. (1973). The fatty acids of Pseudomonas multivorans 
(Pseudomonas cepacia) and Pseudomonas kingii. Joumal of General Microbiology 
74: 275-279.
Santis, G., L. Osbome, et al. (1990). Independent genetic determinants of pancreatic 
and pulmonary status in cystic fibrosis. Lancet 336: 1081-1084.
Schwab, U., A. Wold, et al. (1993). Increased adherence of Staphylococcus aureus 
firom cystic fibrosis lungs to airway epithelial cells. American Review of Respiratory 
Disease 148 365-369.
Segonds, C., E. Bingen, et al. (1997). Genotypic analysis of Burkholderia cepacia 
isolates from 13 French cystic fibrosis centres. Joumal of Clinical Microbiology 35: 
2055-2060.
107
Segonds, C., T. Heulin, et al. (1999). Differentiation of Burkholderia species by PCR- 
restriction fragment length polymorphism analysis of the 16S rRNA gene and 
application to cystic fibrosis isolates. Journal of Clinical Microbiology 37: 2201-2208.
Shaw, D., I. Poxton, et al. (1995). Biological activity of Burkholderia (Pseudomonas) 
cepacia lipopolysaccharide. FEMS Immunology and Medical Microbiology 502: 1-8.
Shelly, B., T. Spilker, et al. (2000). Utility of commercial systems for identification of 
Burkholderia cepacia complex from cystic fibrosis sputum culture. Joumal of Clinical 
Miicrobiology 38: 3112-3115.
Shortridge, V., A. Lazdunski, et al. (1992). Osmoprotectants and phosphate regulate 
expression of phospholipase C in Pseudomonas aeruginosa. Molecular Microbiology 
6:863-871.
Simpson, I., J. Finlay, et al. (1994). Multi-resistance isolates possessing characteristics 
of both Burkholderia (Pseudomonas) cepacia and Burkholderia gladioli from patients 
with cystic fibrosis. Joumal of Antimicrobial Chemotherapy 34: 353-361.
Sinsabaugh, H. and G. Howard (1975). Emendation of the description of 
Pseudomonas cepacia Burkholder (Synonyms: Pseudomonas multivorans Stainer et 
al, Pseudomonas kingae Jonsson; EO-1 Group) Intemational Joumal of Systematic 
Bacteriology 25 187-201
108
Skerman, V., V. McGowan, et al. (1980). Approved lists of bacterial names. 
Intemational Journal of Systematic Bacteriology 30: 225-420.
Smith, D. L., L. B. Gumeiy, et al. (1993). Epidemic of Pseudomonas cepacia in an 
adult cystic fibrosis unit: Evidence of person-to-person transmission. Joumal of 
Clinical Microbiology 31: 3017-3022.
Smith, M., N. Trowers, et al. (1985). Cervical osteomyelitis caused hy Pseudomonas 
cepacia in an intravenous-dmg abuser. Joumal of Clinical Microbiology 21: 445-446.
Smyth, A., D. Heaf, et al. (1993). Transmission of Pseudomonas cepacia by social 
contact in cystic fibrosis (letter). Lancet 342: 434-435.
Snell, J. J., L. R. Hill, et al (1972). Identification of Pseudomonas cepacia 
Burkholder and its synonymy with Pseudomonas kingii Intemational Joumal of 
Systematic Bacteriology 22 127 138.
Snell, G., A. Hoyos, et al. (1993). Pseudomonas cepacia in lung transplant recipients 
with cystic fibrosis. Chest 103: 466-471.
Sokol, P. (1986). Production and utilization of pyochelin by clinical isolates of 
Pseudomonas cepacia. Joumal of Clinical Microbiology 23: 560-562.
Sokol, P., C. Lewis, et al. (1992). Isolation of a novel siderophore from Pseudomonas 
cevacia. Joumal of Medical Microbiology 36: 184-189.
109
Sokol, P. and D. Woods (1988). Effect of pyochelin on Pseudomonas cepacia 
respiratory infections. Microbial Pathogenesis 5: 197-205.
Speert, D., M. Bond, et al. (1994). Infection with Pseudomonas cepacia in chronic 
granulomatous disease: Role of nonoxidative killing by neutrophils in host defense. 
Joumal of Infectious Diseases 170: 1524-1531.
Speller, D., M. Stephens, et al. (1971). Hospital infection by Pseudomonas cepacia. 
Lancet 1: 798-799.
Stanier, R., N. Palleroni, et al. (1966). The aerobic Pseudomonads: a taxonomic study. 
Joumal of General Microbiology 43: 159-271.
Steinbach, S., L. Sun, et al. (1994). Transmissibility of Pseudomonas cepacia 
infection in clinic patients and lung-transplant recipients with cystic fibrosis. The new 
England Joumal of Medicine 331: 981-987.
Stephan, H., S. Freund, et al. (1993). Omibactins-a new family of siderophores fi'om 
Pseudomonas. BioMetals 6: 93-100.
Stoyer, G., D. Drake, et al. (1983). Vimlence of different Pseudomonas species in a 
bumed mouse model: Tissue colonization by Pseudomonas cepacia. Infection and 
Immunity 41:1099-1104.
110
Straus, D. C., M. K. Lonon, et al. (1992). Inhibition of rat alveolar macrophage 
phagocytic function by a Pseudomonas cepacia lipase. Joumal of Medical 
Microbiology 37: 335-340.
Sun, L., R.-Z. Jiang, et al. (1995). The emergence of a highly transmissible lineage of
cbl^ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North 
America and Britain. Nature. Medicine 1: 661-666.
Tabacchioni, S., P. Visca, et al. (1995). Molecular characterization of rhizosphere and 
clinical isolates of Burkholderia cepacia. Research in Microbiology 146: 531-542.
Taplin, D., D. Bassett, et al. (1971). Foot lesions associated with Pseudomonas 
cevacia. Lancet 2: 568-571.
Taylor, R. F. H., L. Dalla Costa, et al. (1992). Pseudomonas cepacia pulmonary 
infection in adults with cystic fibrosis: is nosocomial acquisition occurring. Joumal of 
Hospital Infection 21: 199-204.
Thomassen, M., C. Demko, et al. (1986). Pseudomonas cepacia: decrease in 
colonization in patients with cystic fibrosis. American Review of Respiratory Diseases 
134: 669-671.
I l l
Tipper, J., E. Ingham, et al. (1998). Survival and multiplication of Burkholderia 
cepacia within respiratory epithelial cells. Clinical Microbiology and Infection 4: 450- 
459.
Titball, R. (1998). Bacterial phospholipases. Joumal of Applied Microbiology. 
Supplement 84: 127S-137S.
Tyler, S., C. Strathdee, et al. (1995). Oligonucleotide primers designed to differentiate 
pathogenic pseudomonads on the basis of the sequencing of genes coding for 16S-23S 
rRNA intemal transcribed spacers. Clinical Diagnostic Laboratory Immunology 2: 
448-453.
Tyler, S. D., K. R. Rozee, et al. (1996). Identification of IS7556 a new insertion 
sequence and its association with 1^402 in epidemic strains of Burkholderia cepacia 
infecting cystic fibrosis patients. Joumal of Clinical Microbiology 34:1610-1616.
Urakami, T., C. Ito-Yoshida, et al. (1994). “Transfer of Pseudomonas plantarii and 
Psudomonas glumae to Burkholderia as Burkholderia spp. and description of 
Burkholderia vandii sp. nov.” Intemational Joumal of Systematic Bacteriology 44: 
235-245.
van Pelt, C., C. M. Verduin, et al. (1999). Identification of Burkholderia spp. in the 
clinical microbiology laboratory: Comparison of conventional and molecular methods. 
Joumal of Clinical Microbiology 37: 2158-2164.
112
Vandamme, P., B. Holmes, et al. (1997). Occurrence of multiple genomovars of 
Burkholderia cepacia in cystic fibrosis patients; Proposal of Burkholderia multivorans 
sp. nov. Intemational Joumal of Systematic Bacteriology 47: 1188-1200.
Vandamme, P., E. Mahenthiralingham, et al. (2000). Identification and population 
stmcture of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia Genomovar 
IV). Joumal of Clinical Microbiology 38: 1042-1047.
Viallard, V., I. Poirier, et al. (1998). Burkholderia graminis sp. nov., a rhizospheric 
Burkholderia species and reassessment of [Pseudomonas] phenazinium,
[Pseudomonas] pyrrocinia and [Pseudomonas] glathei as Burkholderia. Intemational 
Joumal of Systemic Bacteriology 48: 549-563.
Visca, P., A. Ciervo, et al. (1993). Iron-regulated salicylate synthesis by Pseudomonas 
spp. Joumal of General Microbiology 139: 1995-2001.
Weingart, C. L. and A. M. Hooke (1999). A nonhemolytic phospholipase C firom 
Burkholderia cevacia. Current Microbiology 38: 233-238.
Welch, D., M. Muszynski, et al. (1987). Selective and differential medium for 
recovery of Pseudomonas cepacia fi'om the respiratory tracts of patients with cystic 
fibrosis. Joumal of Clinical Microbiology 25: 1730-1734.
113
Whitby, P., K. Carter, et al. (2000). Identification of members of the Burkholderia 
cepacia complex by species-specific PCR. Joumal of Clinical Microbiolgy 38: 2962- 
2965.
Whitby, P. W., H. L. N. Dick, et al. (1998). Comparison of culture and PCR for 
detection of Burkholderia cepacia in sputum samples of patients with cystic fibrosis. 
Joumal of Clinical Microbiology 36: 1642-1645.
Wigley, P. and N. Burton (1999). Genotypic and phenotypic relationships in 
Burkholderia cepacia isolated fi'om cystic fibrosis patients and the environment. 
Joumal of Applied Microbiology 86: 460-468.
Wigley, P. and N. Burton (2000). Multiple chromosomes in Burkholderia cepacia and 
Burkholderia gladioli and their distribution in clinical and environmental strains of 
B. cepacia. Joumal of Applied Microbiology 88:914-918.
Wilsher, M., J. Kolbe, et al. (1997). Nosocomial acquisition of Burkholderia gladioli 
in patients with cystic fibrosis. American Joumal of Respiratory and Critical Care 
Medicine 155:1436-1440.
Wretlind, B. and O. Pavlovskis (1981). The role of proteases and exotoxin A in the 
pathogenicity of Pseudomonas aeruginosainlecXiom. Scandinavian Joumal of 
Infectious Diseases Supplement 29: 98-101.
114
Yabuuchi, E., Y. Kawamura, et al. (2000). Burkholderia uboniae sp. nov., L- 
arabinose-assimilating but different from Burkholderia thailandensis and 
Burkholderia vietnamiensis. Microbiology and Immunology 44: 307-317.
Yabuuchi, E., Y. Kosako, et al. (1992). Proposai of Burkholderia gen. nov. and 
transfer of seven species of the genus Pseudomonas homology group II to the new 
genus with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb, 
nov. Microbiology and Immunology 36 897-904
Yabuuchi, E., Y. Kosako, et al. (1995). Transfer of two Burkholderia and an 
Alcaligenes species to Ralstonia gen. nov.: proposal of Ralstoniapickettii f^dXsXon, 
Palleroni and Doudoroff 1973) comb. nov. Ralstonia solanacearum (Smith 1996) 
comb. nov. and Ralstonia eutropha (Davis 1969) comb. nov. Microbiology and 
Immunology 39: 897-904.
Zhao, N., C. Qu, et al. (1995). Phylogenetic evidence for the transfer of Pseudomonas 
cocovenenans (Vandamme et al. 1960) to the genus Burkholderia as Burkholderia 
cocovenenans (Vandamme et al. 1960) comb. nov. Intemational Joumal of Systematic 
Bacteriology 45: 600-603.
Zughaier, S., H. Ryley, et al. (1999). Lipopolysaccharide (LPS) from Burkholderia 
cepacia is more active than LPS from Pseudomonas aeruginosa and 
Stenotrophomonas maltophiliain stimulating tumour necrosis factor from human 
monocytes. Infection and Immunity 67: 1505-1507.
115
Zughaier, S., H. Ryley, et al. (1999). A melanin pigment purified from an epidemic 
strain of Burkholderia cepacia attenuates monocyte respiratory burst activity by 
scavenging superoxide anion. Infection and Immunity 67:908-913.
116
6. Appendicies 
6.1. Appendix 1
6.1.1. Malka minimal medium (Butler et al 1995)
Solution A
Reagent gm per litre Concentration
Na2HP04 73.4 X 50
KH2PO4  32.4
5-10 ml chloroform to 100 ml to sterilise 
Solution B
Reagent gm per litre Concentration
20.5 X50MgS04  
H2O
5-10 ml chloroform to 100 ml to sterilise 
Solution C
Reagent Molarity Concentration
Mono- 1 M X 50
sodium L
glutamate
Sterilise by filtration 
Solution D
Reagent gm per litre Concentration
1.83 XIOOOFeS0 4  
7H2O
One drop of H2 SO4 added to sterilise
Solution E
Reagent gm per litre Concentration
(NH4)2S04 50 X 50
Make up to 200 ml with sterile distilled water
Total volume in ml
20
Total volume in ml
20
Total volume in ml
20
Total volume in ml
Total volume in ml
20
Mix sterile solutions
20A + 20B + 2 0 c  + ID + 20B + 919 distilled water
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6.2. Appendix 2
6.2.1. Preparation of SDS-PAGE buffers and enzyme solutions (Laemmli 1970)
Reagent
Tris
Sterile distilled water 
pH 8.8
Reagent
Tris
Sterile distilled water 
pH 6.8
Reagent
Tris 
Glycine 
10 % SDS
Resolving gel buffer
Weight /volume
45.4 gm 
500 ml
Stacking gel buffer
Weight /volume
15.12 gm 
250 ml
Reservoir buffer 
Weight /volume
1.2 gm 
5.76 gm 
4 ml
Concentration
0.75 M
Concentration
0.75 M
Concentration
0.025 M 
0.192 M 
0.1 %
Make up to 400 ml with sterile distilled water
Reagent
Glycerol 
Stacking gel buffer 
10 % SDS 
2-mercaptoethanol 
Sterile distilled water 
Total Volume
x2 Sample buffer 
Volume (ml)
10
12.5 
20 
1
6.5 
50
Concentration
2 0 % 
0.125 M 
4%
2 %
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0.25 % Protease K stock solution
Reagent Volume (ml)
Glycerol 2
Stacking gel buffer 2.5
10% SDS 4
Sterile distilled water 11.5
0.05 gm Protease K
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6.3. Appendix 3
6.3.1. SDS-PAGE gels and staining solutions (Laemmli 1970)
Preparation of 10 % acrylamide resolving gel for two mini-gels 
Reagent Volume (ml)
30 % acrylamide solution 
0.75 M resolving gel buffer 
10 % SDS 
Sterile distilled water 
1.5% ammonium persulphate
TEMED 10 pi
6.7
10
0.2
2.1
1
Preparation of 5 % acrylamide stacking gel for two mini-gels 
Reagent Volume (ml)
30 % acrylamide solution 
0.5M stacking buffer 
10 % SDS 
Sterile distilled water
1.5 % ammonium persulphate
TEMED 10 pi
1.7
10
0.1
5.2
0.5
Chemical
Methanol 
Glacial acetic acid 
Periodic acid
Chemical
Sodium hydroxide 
Ammonium hydroxide 
Silver nitrate
Silver stain fixing solution
Weight/volume
900 ml 
300 ml 
100 ml
Silver stain
Weight/volume
14 ml 
1.0 ml
2.5 ml
Concentration
0.7 %
Concentration
0.1 M
20%
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Silver stain developing solution
Chemical Weight/volume Concentration
Sodium carbonate 50 ml 0.28 M
Formalin 1.0 ml 40 %
Sodium thiosulphate 4.0 ml 4.3 %
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6.4. Appendix 4
6.4.1. Table 25 Summary of biochemical assays, plate assays, presence of 
epidemiological markers and epidemiological typing of B.cepacla isolates
Hosp Genom CA IH ESM RAPD SS Cas Lee Gel Hyn
1 B.gladioli + 
1
+ + E R - + - ++
2 l/IV - - - NE S N - + - -
2 l/IV - - - NE R ++ + - +++
3 l/IV - - - NE R - - - ++
4 l/IV - - + NE S N + - - +
5 l/IV - - - NE S N + + - ++
6 l/IV - - - NE S N -/+ + - +++
7 l/IV - - + NE S Y ++ ++ + +
8 l/IV - - - NE S N + + - ++
9 l/IV
9
- - NE R - + - -
10 II - - - NE R - + - -
2 II - - - NE S Y - - - -
2 II - - + NE R - - - -
6 II - - - NE S Y - - - -
6 - - - NE S Y - - - -
11 II - - - NE R - + - -
12 II - - - NE R - - - -
13 II - - - NE R - - - -
13 II - - - NE R - + - -
13 II - - - NE R - + - -
14 II - - - NE R - - - -
7 II - - - NE R - + - -
15 ■■ - - - NE R - + -
15 II - - - NE S Y - - - -
15 II - - + NE R - + - -
15 II - - - NE R - - - -
16 II - - - NE R - - - -
16 II - - - NE R - - - -
17 II - - - NE R - + - -
18 II - - - NE R - + - -
19 II - - - NE R - - - -
20 II - - + NE R - + - -
20 II - - - NE R - +/- - -
1 II - - - NE R - + - -
1 II - - - NE R - + - -
1 II - - - NE 1 Y - + - -
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1 II - - - NE R - - - -
1 II - - - NE S Y - + - -
1 II - - - NE R - + + -
1 II - - - NE R - - - -
1 II - - - NE R - - - ■ -
1 II - - - NE R +/- - - -
1 - - - NE R - + - -
1 II - - - NE R - + - -
21 II - - - NE R - + - -
22 II - - - NE S Y - - - -
23 II - - - NE S Y - + - -
24 II - - - NE S Y - + - -
25 II - - - NE R - + - -
26 II - - - NE R - - - -
27 II - - - NE R - - - -
28 II - - + NE S Y + + + -
29 II - - + NE R - - - -
29 II - - + NE R - + - -
5 II - - - NE R - - - -
5 II - - - NE R - + - -
5 II - - - NE R - + - -
30 II
48
- - NE R - + - -
2 Ilia - - - NE R ++ ++ - +++
+
6 Ilia - - - NE 1 Y + + - +++
+
6 Ilia - - - NE R + + - -
31 Ilia - - - NE R + + - +++
+
15 Ilia - - + NE 1 Y ++ + - +/-
8 Ilia + + + E 1 N - - - +
32 Ilia - - - NE R ++ + - +++
33 Ilia + + + E 1 N + - - +
3 Ilia - - + NE R + + - +
34 Ilia - - - NE R + + - +
22 Ilia - - - NE R + + - +++
9 Ilia - - - NE R ++ + - -
5 Ilia + + + E 1 N + -/+ - +
5 Ilia + + + E 1 N + - - +
5 Ilia + + + E 1 N + - - +
5 Ilia + + + E 1 N + - - +
5 Ilia + + + E 1 N + - - +
5 Ilia + + + E 1 N + - - +
5 Ilia + + + E 1 N + - - +
5 Ilia - - - NE S Y + + + +
5 Ilia + + + E 1 N + - - +
5 Ilia +
22
+ + E R + - - +
6 lllb + + + E S N - - - -
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35 lllb - - - NE S Y - + - -
32 lllb - - - NE S Y - + + +++
+
36 lllb
4
- + NE R + + - -
37 lllc - - - NE R - - - -
3 lllc - - - NE S - - - -
38 lllc + + + E S N - - - -
8 lllc + - + E S - +/- - -
8 lllc + + + E 1 N - - - -
8 lllc + + + E S - - - -
8 lllc - - + NE R - - - -
8 lllc + - + E S N +/- - - -
8 lllc + + + E S +/- - - -
33 lllc + + + E 1 N -/+ - - +
1 lllc + + + NE 1 - - - -
1 lllc + + + E S N - - - -
1 lllc + + + E 1 N - - - -
1 lllc - - - NE R - - - -
1 lllc - - - NE R - - - -
39 lllc + + + E S N - - - -
40 lllc + + + E R - - - -
40 lllc + + + E 1 N +/- +/- - -
40 lllc + + + E 1 N + + - -
40 lllc + + + E 1 + - - -
40 lllc + + + E 1 N - - - -
40 lllc + + + E S N - +/- - +++
41 lllc + + + E 1 N - - - -
3 lllc + + + E R - - - -
22 lllc + + + E 1 N - - - +
22 lllc + + + E 1 N - - - -
22 lllc + + + E 1 N - - - ++
22 lllc + + + E 1 N - - - -
40 lllc + + + E 1 N - - - -
40 lllc + + + E 1 N - - - -
21 lllc + + + E 1 N - - - -
41 lllc +
32
+ + E 1 N - - - ++
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Genom: genomovar 
CA: CblA
IH: Insertion Sequence hybrid 
ESM: Epidemic strain marker
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SS: Serum sensitive 
Bl. Sensitivity blocked 
Cas: Casein hydrolysis 
Lee: Lecithinase production 
Gel: Gelatin hydrolysis 
Hyn: Haemolysin production 
R: Resistant 
S: Sensitive 
N: No 
Y; Yes 
E: Epidemic 
NE: Non-epidemic
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